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ABSTRACT 
 
The to be carefully regulated to avoid unscheduled targeting structure-
specific endonuclease MUS81/EME1 plays important roles in the 
resolution of recombination intermediates, however, its function needs 
intermediates during DNA replication, which may result in genome 
instability. Little is known about the regulation of the human MUS81 
complex. Hence, we undertook a proteomic analysis to identify 
regulatory phosphorylation events of MUS81. Our analysis identified 
several hits and among them we functionally characterized the residue 
targeted by the pleiotropic kinase CK2. Using biochemical and cell 
biological approaches, we demonstrated that accurate MUS81 
phosphorylation on S87 by CK2 is not required to prevent DNA 
damage in S-phase but for resolution of branched DNA intermediates 
in mitosis, which is crucial to facilitate proper DNA segregation under 
replication stress but contributes modestly to chromosome integrity. 
However, constitutive S87 MUS81 phosphorylation triggers DNA 
damage and largely undermines genome integrity in normal cells. 
Next, using our S87-MUS81 phosphorylation mutant as a tool to 
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define which function of MUS81, the S-phase-related one or that 
performed in M-phase, was essential under pathological conditions. 
As a prototype of pathological condition, we used BRCA2-deficient 
cells that needs MUS81 to recover from replication stress. Using cell 
biology approaches to evaluate survival, DNA damage and resolution 
of mitotic interlinked intermediates, we show that the S87 MUS81 
phosphorylation is involved to ensure viability of BRCA2-deficient 
cells mostly because it is the M-phase function of MUS81 to be 
essential.  
Altogether, our data described a novel regulatory mechanism required 
to control MUS81 complex function in M-phase in human cells and 
involved in the viability of BRCA2-deficient cells. As CK2 inhibitors 
are under evaluation as anti-cancer drugs, our data may be useful to 
evaluate their use in tumors with signs of BRCAness. 
  
8 
 
INTRODUCTION 
1 DNA Replication 
Since the discovery of the DNA structure more than 50 years ago, the 
remarkable mechanisms that preserve the genetic information encoded 
by DNA and guarantee its faithful transmission across generations 
have been the subject of extensive investigation (Ciccia & Elledge, 
2010). During every S phase, cells need to duplicate their genomes so 
that both daughter cells inherit complete copies of genetic information. 
DNA replication is regulated by recruiting the replication machinery 
or “replisome” to sites called origins on the chromosome. Replication 
must be strictly coordinated with the cell cycle to ensure faithful 
duplication of the genome. The replisome is a molecular machine that 
replicates the DNA bi-directionally from origins in a semiconservative 
fashion. The recruitment process is called initiation, whereas 
subsequent replication of the DNA by the replisome is called 
elongation. The replisome opens the DNA helix, stabilizes the ssDNA 
that is formed, and allows enzymes (polymerases) to copy the DNA 
(Sclafani & Holzen, 2007). The first step in replication initiation is the  
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assembly of pre-replicative complexes (pre-RCs) at replication 
origins, a process known as licensing. During licensing, the core 
replicative helicase component, the hexameric mini-chromosome 
maintenance 2-7 (MCM) complex, is loaded around double-stranded 
DNA as an inactive double hexamer (Fig.1). Loading MCM requires 
several other pre-RC factors: the six-subunit origin recognition 
complex (ORC; subunits Orc1-6), Cdc6 (cell division control protein 
6) and Cdt1. At the G1/S transition, two kinases, CDK and Dbf4-
dependent kinase (DDK) activate the MCM helicase, which involves 
the recruitment of Cdc45 and the heterotetrameric GINS complex to 
form the CMG complex. The conversion of pre-RCs into bidirectional 
replisomes requires a host of other factors, including Sld2 (RecQL4 in 
metazoans), Sld3 (Treslin/TICRR in metazoans), Sld7, Mcm10 and 
Dpb11 (TopBP1 in metazoans) (Hills & Diffley, 2014). Elongation 
factors are then recruited, many of them via interactions with the core 
homo-trimeric sliding clamp PCNA (Rowlands et al., 2017). At each 
fired origin, two sister replication forks (RFs) are established that 
move away from the origin as the parental DNA duplex is unwound 
by the action of DNA helicases. When one RF is terminally blocked 
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or arrested, firing of dormant or nearby origins ensures that replication 
is complete(Branzei & Foiani, 2010).  
 
 
 
 
 
 
 
 
Figure 1 Replication initiation and progression. (a) Replication begins from multiple 
origins, which are marked by the formation of a pre-replicative complex (preRC).(b) 
Two replication forks (RFs), which are associated with the replisome that carries out 
DNA replication, are established at each fired origin. The minichromosome 
maintenance (MCM) helicase complex is shown ahead of the RFs, unwinding the 
duplex DNA. Replication is semi discontinuous: DNA synthesis is continuous on the 
leading strand and discontinuous on the lagging strand, on which primers are 
elongated to form Okazaki fragments that are processed and ligated to one another. 
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(c) Numerous proteins are present at the RF. The MCM helicase unwinds the parental 
duplex, allowing access to the DNA polymerase-α (Polα) primase, replicative 
polymerase-δ (Polδ) and polymerase-ε (Polε) (which elongate the primers) and the 
replication processivity clamp proliferating cell nuclear antigen (PCNA; also known 
as Pol30), which is loaded by the clamp loader, the replication factor C (RFC) 
complex. Replication protein A (RPA) binds single-stranded DNA regions exposed at 
the RF or during lagging-strand synthesis. The discontinuous fragments synthesized 
on the lagging strand are processed by Rad27 (FEN1 in humans), Dna2 helicase, 
RNase H, Polδ and DNA ligase I (LigI). Several other factors associate with the RF 
in yeast and are represented: DNA topoisomerases 1 (Top1) and Top2, the checkpoint 
mediators mediator of replication checkpoint protein 1 (Mrc1), Top1-associated factor 
1 (Tof1) and chromosome segregation in meiosis protein 3 (Csm3), and the Rrm3 
helicase (Branzei and Foiani, 2010).   
Although the bulk of DNA replication is completed during S-phase, it 
has been known for some time that certain regions of the genome can 
show a delay in completion of DNA replication. While this was 
generally assumed to be occurring during the G2 phase, recent data 
indicate that DNA synthesis can still occur after the cells have initiated 
the prophase of mitosis. This process, called MiDAS (for mitotic DNA 
synthesis), appears to be a form of homologous recombination-based 
DNA repair. MiDAS is more prevalent in aneuploid cancer cells (or  
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otherwise transformed cells), where it counteracts DNA replication 
stress that arises at ‘difficult-to-replicate’ loci (Özer & Hickson, 
2018), of them the best characterized examples are the ribosomal 
DNA (rDNA), chromosome fragile sites and telomeres (Gadaleta & 
Noguchi, 2017). Particularly important are common fragile sites 
(CFS) because in response to RS, the FANCD2/FANCI protein 
complex forms ‘‘twin foci’’ (one on each sister chromatid) at CFS loci 
that can persist into mitosis and their mitotic DNA synthesis requires 
MUS81-EME1, SLX4, and a non-catalytic subunit of DNA 
polymerase δ, POLD3 (Pol32 in yeast) (Bhowmick et al., 2016a). The 
consequences of MiDAS failure and progression through mitosis with 
unreplicated DNA could be not only the formation of mitotic 
aberrations such as anaphase bridges, lagging chromatin and 
chromosome breaks/gaps, but also genomic instability in the next G1 
cell cycle of daughter cells, which can acquire an incorrect 
chromosome number/structure (Özer & Hickson, 2018). Genomic 
instability refers to a higher rate of chromosomal aberrations, 
including simple gene mutations, as well as more extensive 
chromosomal structural and numerical changes (aneuploidy).  
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Mutations or epigenetic changes in DNA repair and cell cycle 
checkpoint genes are key drivers of genome instability, particularly in 
hereditary cancers. For sporadic cancers, an additional pathway for 
acquiring genomic instability is through the development of 
oncogene-induced DNA replication stress (Zhang et al., 2018). On this 
basis, the replication of the genome must be an exact process. Errors 
that result in under replication or over replication of the genome in any 
cell cycle have disastrous consequences and can produce a large array 
of human genetic diseases, including cancer, birth defects, and many 
developmental abnormalities. Molecular regulatory mechanisms have 
evolved to ensure that the genome is replicated once and only once 
and then segregated equally to the resultant daughter cells (Sclafani & 
Holzen, 2007).  
1.1 Replication fork stalling  
The replication fork progression is constantly faced with different 
endogenous or exogenous impediments all along the genome. 
Exogenous barriers include DNA damage produced by genotoxic 
components from the environment, radiation, therapeutic treatments 
and the diet. In contrast, endogenous obstacles come from inherent 
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DNA structures and composition, protein-DNA complexes, 
modification of the nucleotide pool, the production of oxidative 
species, transcription- replication machinery collisions, mutations in 
tumor suppressor genes and oncogenic protein expression (Branzei & 
Foiani, 2010). DNA damage can be produced also by chemical agents 
used in cancer chemotherapy like mitomycin C (MMC), cisplatin, 
psoralen and methyl-methane sulfonate (MMS), or other one such as 
the topoisomerase inhibitors camptothecin and etoposide, which 
induce the formation of single (SSBs) and double (DSBs)-strand 
breaks, respectively, by trapping covalently linked topoisomerase-
DNA cleavage complexes. Other drugs, like hydroxyurea and 
aphidicolin, impair the progression of replication by depleting 
deoxyribonucleotide pools or inhibiting DNA polymerase (Mehta & 
Haber, 2014).These damaged or difficult-to-replicate DNA regions 
induce replication fork slowing or stalling, also known as “replicative 
stress”(Zeman & Cimprich, 2014). The stalling of replication forks 
opens up the risk of fork collapse and damage to DNA. To prevent 
such adverse effects, cells engage a variety of factors that stabilize the 
paused forks and aid the timely resumption of elongation (Rowlands  
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et al., 2017). Replicative stress is mediated by the uncoupling of 
helicases from DNA replicative polymerases, generating long 
stretches of single-stranded DNA (ssDNA) (Byun et al., 2005). This 
situation leads to S-phase checkpoint activation in order to organize 
replication fork restart (Bournique et al., 2018). The hallmark of DNA 
damage response (DDR) is the activation of checkpoints to 
temporarily delay cell cycle progression through inhibition of cyclin-
dependent kinase activity, activate DNA repair system or induce 
cellular apoptosis/senescence. So eukaryotic cells evolved a plethora 
of enzymatic activities that chemically modify DNA to repair DNA 
damage including nucleases, helicases, polymerases, topoisomerases,  
recombinases, ligases, glycosylases, demethylases, kinases and 
phosphatases. The link between defects in the DDR and cancer 
pathogenesis has been established via multiple lines of evidence. 
These include: (i) genetic studies, where defects in tumour suppressor 
genes that control the DDR (e.g.BRCA1, BRCA2, PALB2, RAD51C, 
RAD51D, FANC-family genes, MLH1, etc. (Lord & Ashworth, 2012) 
predispose to familial forms of cancer; (ii) cytogenetic and genomic 
studies, where the number and type of different DNA mutations and  
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forms of genomic instability found in human tumours often betray the 
DNA repair defects that have moulded tumour genomes (Alexandrov 
et al., 2013);  and (iii) functional studies, where experimental 
induction of specific DNA repair defects causes cancer in animal 
models (Kersten et al., 2017). The ability of DDR defects to result in 
disordered, mutated genomes might also be enhanced by commonly 
occurring defects in gatekeeper tumour suppressor genes such as p53, 
ATR, ATM, CHK1 and CHK2 (Jackson & Bartek, 2010). In budding 
yeast, sensing of DNA damage or stalled replication forks relies on the 
Rad24-dependent loading of the heterotrimeric Rad17-Mec3-Ddc1 (9-
1-1 complex in fission yeast and humans) sliding clamp onto DNA. 
This leads to Mec1 kinase (ATR in humans) activation, followed by 
the downstream phosphorylation and activation of the primary 
signalling kinase Rad53. In higher eukaryotes, central component of 
the DDR is the  phosphatidylinositol 3- kinase-like protein kinases 
(PIKKs) family ATM, ATR and DNA-PK  and members of the 
poly(ADP)ribose polymerase (PARP) family (Ciccia & Elledge, 
2010). ATR activation primarily leads to Chk1 kinase activation 
during the S-phase checkpoint, rather than Rad53 homolog Chk2.  
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Mec1-dependent activation of Rad53 requires the adaptor Mrc1 
(Claspin in humans), which forms a complex to stabilize replication 
forks at sites of replication stress. Several other proteins function to 
promote Rad53 activation, including Rad9, Csm3, and Tof1 
(Chaudhury & Koepp, 2016). ATM and DNA-PK respond mainly to 
DSBs, whereas ATR is activated by ssDNA and stalled replication 
forks. ATM (Ataxia telangiectasia mutated) is 350 kDa oligomeric 
protein and it exhibits significant homology to phosphoinositide 3-
kinases (PIKK). In humans, mutations in ATM cause ataxia 
telangiectasia, a rare autosomal recessive disorder characterized by 
genome instability, immunodeficiency and predisposition to cancer 
(Abraham et al., 2001). These genes normally encode proteins whose 
function is to induce cell cycle arrest in response to DNA damage; the 
partial or complete inactivation of these gatekeeper tumour 
suppressors often allows cells to circumvent cell cycle checkpoints 
and to continue to proliferate even in the face of persistent DNA 
damage (Lord & Ashworth, 2012). Similarly, the inactivation of 
specific tumour suppressor proteins such as ATM, allows cells to 
proliferate in the face of replication fork stress, i.e. the stalling or 
slowing of replication forks.  
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This replication fork stress appears to be a feature of pre-neoplastic 
lesions and is associated with the activation of oncogenes such as 
Cyclin E (CCNE1) or Myc.  
 
1.2 Replication fork restart  
As mentioned above replication fork stress can also arise through a 
variety of additional causes, including an excess of naturally occurring 
secondary structures within the DNA double helix, therapy induced 
DNA lesions that stall replication forks, nucleotide depletion, 
collisions between the replication and transcription machinery, or an 
enhanced incorporation of ribonucleotides into DNA (Zeman & 
Cimprich, 2014).  
Replication checkpoints are involved in modulating the replication 
fork response to intra-S damage by stabilizing the stalled fork and the 
association of the replisome with the fork through restraining the 
activity of recombination enzymes at stalled forks (Branzei & Foiani, 
2005). In addition to protecting the stalled forks from collapsing, 
replication checkpoints are also thought to mediate the damage 
response that promotes replication resumption following fork  
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collapse. As a rule of thumb, mechanisms involved in replication fork 
recovery can be grouped in two: those depending on direct restart of 
the fork and those being recombination-dependent (Fig.2) (Franchitto 
& Pichierri, 2014). 
 
 
 
 
 
Figure 2 Pathways by which DNA replication can reinitiate after replication fork 
arrest. Upon stalling of a replication fork, DNA synthesis can be reinitiated through 
three different mechanisms (from top to bottom): replication can be restarted by 
repriming downstream of the site of stalling; alternatively, specialized enzymes, such 
as DNA translocases and helicases, are recruited to remodel the DNA at stalled forks 
to produce a regressed fork, which is used to protect ssDNA at the site of fork stalling 
and to restore a functional replication fork; finally, replication can be resumed using 
recombination from either collapsed forks, after production of one-ended DSBs, or 
from the regressed replication fork. Perturbation of replication at CFS most probably 
engages a non- recombinogenic pathway of fork restart (Franchitto & Pichierri, 2014). 
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The direct restart of the fork has been originally demonstrated in 
bacteria, and requires the PriA and PriC proteins (Heller & Marians, 
2005, 2006).  
Even if homologs of PriA and PriC have not been found in eukaryotes, 
indirect evidence of the presence of a similar mechanisms in higher 
eukaryotes does exist. Using Xenopus extracts, it has been 
demonstrated that Polα primase, which is essential for initiation and 
elongation of DNA synthesis, can be recruited also at ssDNA regions 
formed after replication fork stalling (Van et al., 2010). Whether the 
Polα primase can be recruited at ssDNA regions accumulating after 
fork arrest also in human cells, is not known, however, a recent paper 
demonstrated that loss of MCM10 leads to replication stress (Miotto 
et al., 2014). Interestingly, Polα primase interacts with MCM10 during 
initiation and elongation (Zhu et al., 2007). 
Recombination-based restart mechanisms are probably most relevant 
to collapsed forks where the replication machinery has been lost, thus 
facilitating Holliday junction formation. The recombination factor 
Rad51 (which catalyzes Holliday junctions) can be recruited to stalled 
forks (Petermann et al., 2010). Helicases that function in Holliday  
 
21 
 
junction resolution during recombination, including the RecQ helicase 
family members Bloom Syndrome protein BLM and the Werner 
Syndrome protein WRN have demonstrated roles in fork restart 
(Franchitto et al., 2008). This activity is conserved, as the related 
protein in budding yeast, Sgs1, is important for recombination-
mediated fork restart. Replication fork restart is also linked to Fanconi 
Anemia (Moldovan & D’Andrea, 2013). Although members of this  
group are best known for their roles in interstrand crosslink repair, the 
FANCD1, FANCD2, and FANCJ proteins have distinct roles in 
replication fork restart. In particular, FANCD2 is required to stabilize 
and recruit BLM to stalled forks (Chaudhury et al., 2013; 
Raghunandan et al., 2015). In addition to recombination factors, 
conserved scaffold proteins such as Slx4 and Rtt107 that interact with  
structure-specific nucleases or fork repair proteins are also important 
for fork restart (Chaudhury & Koepp, 2016; Ohouo et al., 2010). 
Finally, forks that cannot be recovered may be bypassed by the firing 
of nearby “back-up” origins, ensuring that chromosome duplication is 
completed blow (Jackson, & Blow, 2007; Woodward et al., 2006).  
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1.3 Repair mechanisms 
Despite the complex response initiated by the cell to stabilize and 
restart a stalled fork, the fork may fail to restart and “collapse”, 
particularly if replication stress persists or replication stress response 
components are lost. The physical structure and protein composition 
of both stalled and collapsed replication forks is still under 
investigation (Zeman & Cimprich, 2014). To counteract DNA 
damage, repair mechanisms specific for many types of lesion have 
evolved. While DNA single strand breaks (SSBs) are repaired by 
mechanisms of nucleotide excision repair (NER) or base excision 
repair (BER), or mismatch repair (MMR), DNA double strand breaks 
(DSBs)s are repaired either by the mechanism of homologous 
recombination (HR), which utilizes the sister chromatid as a template 
for a correct replacement of the DNA sequence, or by the mechanism 
of non-homologous end joining (NHEJ), which is more prone to errors 
(Friedberg et al., 2006; Hoeijmakers, 2001). 
The cellular choice of using HR or NHEJ is largely dependent on the 
phases of the cell cycle; NHEJ is present throughout the cell cycle, 
whereas HR predominates in the S and G2 phases, in order to ensure  
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the high-fidelity preservation of genetic information (Helleday, 2003). 
If the repairing process does not occur correctly, the DNA injuries 
result in mutations and chromosomal aberrations which alter the 
cellular behavior and lead to cancer. Genes that encode for enzymatic 
or scaffolding proteins involved in the “core” DDR activities are: 
XPA-XPG, RPA, ERCC1, DNA glycosylase, APE1, DNA 
polymerase β/δ/ε, XRCC1, DNA ligase 1/3, DNA ligase IV, Ku70/80, 
RAD50/MRE11/NBS1, BRCA1, BRCA2, and RAD51 (Fig. 3) (Davis 
& Chen, 2013; Fortini et al., 2003; Kowalski et al., 2009; Leng et al., 
2012; Stracker and Petrini, 2014; Yang et al., 2013).Furthermore, 
ubiquitination, sumoylation, acetylation and methylation processes 
provide an additional layer of complexity targeting stability and 
efficiency of DDR proteins machinery (Huen & Chen, 2008; Polo & 
Jackson, 2011). 
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Figure 3 Diagram of targeted DDR pathways. In the lower part of the figure the DDR 
mechanisms and the related proteins involved are represented. In the upper part of the 
figure the targeting strategy for the corresponding defective DDR mechanisms are 
shown (Cerrato, Morra, & Celetti, 2016). 
As mentioned above one important DNA repair mechanism to 
maintain genomic integrity is recombination. It is an important 
mechanism to repair nicks, gaps, breaks, or stalled forks to prevent 
chromosome fragility and protect cell health. Damage that results in 
DSBs can be repaired by various types of end-joining, by annealing of 
processed ends, or by recombination-based mechanisms using either a 
sister chromatid or homolog as the template (Jinxue He, Xi Kang, 
Yuxin Yin, K.S. Clifford Chao, 2016).  
There are at least two hypotheses for how a stalled fork may be 
processed into a DSB. First, it may be an attempt by the cell to resolve 
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an otherwise irresolvable stalled fork structure using endonucleolytic 
cleavage and recombination-based restart pathways (Hanada et al., 
2007; Petermann et al., 2010; Segurado & Diffley, 2008). This 
response could be initiated by the formation of vulnerable structures 
(a reversed fork, stalled fork, or ssDNA), or could be a symptom of 
the aberrant activation of nucleases in the absence of ATR. Second, 
persistent ssDNA alone, found at the stalled fork, in gaps left behind 
the fork, or in structures which arise from these gaps, may also be 
targeted by endonucleases or prone to passive breakage under 
prolonged stalling conditions (Lopes et al., 2001; Lopes, Foiani, & 
Sogo, 2006; Sogo, Lopes, & Foiani, 2002). As noted, recent evidence 
 has also suggested that stalled replication forks can reverse, 
rewinding the parental DNA and extruding the newly replicated 
strands in a “chicken foot” structure (Fig. 4b,c) (Zeman & Cimprich, 
2014).  
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Figure 4 Mechanisms of stalled replication fork restart and collapse (a) The ATR-
mediated replication stress response. ATR and its obligate binding partner ATRIP are 
activated by a primer-template junction at the stalled replication fork, where ATR 
initiates a signalling cascade primarily mediated by the effector kinase Chk1. This 
response promotes fork stabilization and restart, while preventing progression through 
the cell cycle until replication is completed.(b) Mechanisms for the restart / rescue of 
stalled forks. Replication forks stalled at DNA lesions (shown here on the leading 
strand, red star) and stabilized by the ATR pathway can restart replication by firing 
dormant origins, repriming replication, reversing the stalled fork or activating the 
DNA damage tolerance pathways. Key intermediates in these restart pathways are  
illustrated. (c) Mechanisms of fork collapse. If stalled forks are not stabilized, or 
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persist for extended periods of time, replication forks will collapse, preventing 
replication restart. The mechanism by which a replication fork collapses is still 
ambiguous, and several possibilities are presented here, including dissociation of 
replisome components, nuclease digestion of a reversed or stalled fork (middle panels) 
or replication run-off. (Zeman and Cimprich, 2014). 
 
1.3.1 Homologous recombination 
Among the DSB- repair pathways, HR- and single-strand annealing 
(SSA) require extensive resection, whereas non-homologous end-
joining (NHEJ) and alternative end-joining/microhomology-mediated 
end joining (aEJ/MMEJ) require little or no resection (Fig. 5). 
Elaborate control of DSB end resection appears to be the critical point 
of DSB pathway choice, this regulation involves extensive chromatin 
remodelling, histone modifications, the Ku70–80 heterodimer, the 
checkpoint adaptor Rad9 (yeast) or its homologs 53BP1 (mammals), 
and RIF1. It appears that control of DSB end resection represents a 
key difference between DSB repair in yeast and mammalian cells, 
although the end resection machineries are largely conserved (Heyer 
et al., 2015). HR is a template-dependent process and in somatic cells 
there is a significant bias toward the sister chromatid, although there  
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is evidence for HR between homologs in the G1 phase of the cell 
cycle. Control of DSB end resection appears to be a critical component 
and only recently been established by genetic and biochemical 
approaches that have elucidated a two-step mechanism involving 
nucleases and helicases. A key conserved target for cell-cycle-
dependent kinases in the end-resection machinery was identified as 
yeast Sae2 and its mammalian homolog CtIP (Huertas & Jackson, 
2009). Sae2/CtIP cooperate with the Mre11/Rad50/Xrs2 (mammalian 
MRE11/ RAD50/NBS1) complex to provide the initial resection of 
DSBs. It is unclear whether Sae2/ CtIP phosphorylation affects the 
MRE11-associated exo- and endonuclease activities, which 
differentially affect pathway choice in DSB repair (Cannavo and 
Cejka, 2014; Lengsfeld et al., 2007; Atsushi et al., 2014). In addition, 
yeast Dna2, a nuclease/helicase that cooperates with Sgs1 and RPA in 
long-range resection, is recruited to DSBs in a CDK-phosphorylation-
dependent manner (Chen et al., 2015). 
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Figure 5 Homologous recombination (HR) and pathway choices. The pathways of 
double-strand break (DSB) repair include non homologous end joing (NHEJ), 
alternative end joining (aEJ, also called microhomology- mediated end joining), 
which are differentiated whether the joint involves no or few nucleotides (1–5 nt) or 
greater (5–25 nt) homology. Single-strand annealing (SSA) is possible when the DSB 
is flanked by direct repeat sequences and requires extensive resection. HR includes 
several sub pathways including break-induced replication (BIR), which leads to loss 
of heterozygosity, synthesis-dependent strand-annealing (SDSA), which leads to a 
noncrossover outcome, and the double Holliday junction pathway (dHJ), which 
through nucleolytic resolution of dHJs generates crossover and non crossovers 
outcomes. Dissolution of dHJs, in contrast, leads exclusively to non crossover 
products (Heyer et al., 2015). 
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Three distinct nucleases (MRE11, EXO1, and DNA2), a RecQ 
helicase (Sgs1 in budding yeast and either BLM or WRN in humans 
and other mammals), and other several molecular factors are involved. 
First, this pathway includes the MRN complex.  
The MRE11 subunit has 3’-5’ exonuclease activity on single or double 
stranded DNA, and its homodimerization promotes binding to DNA 
and interaction with RAD50 (Williams et al., 2008). RAD50 
stimulates MRE11 DNA binding and nuclease activity and facilitates 
DNA tethering for the MRN complex (MRE11, EXO1, and DNA2). 
NBS1 has no known enzymatic activities, but its recruitment to DSBs 
is essential for activation of ATM and initiation of DDR. NBS1 has a 
phosphopeptide binding FHA domain and structurally divergent 
tandem BRCT repeats linking the core MRN activities to proteins 
phosphorylated in response to DNA damage.  
An important protein interacting with NBS1 through the FHA/BRCT 
domains is CtIP (Sae2 yeast homologous). CtIP plays an essential role 
in the activation of the MRN complex and the initiation of resection 
(Makharashvili et al., 2014; Eid et al. 2010). Since the MRN nuclease 
activity cannot generate the products observed after resection at DSBs,  
31 
 
it is though that MRN plays a role only in the initial stages of the 
pathway. Indeed, MRN complex provides the MRE11 nuclease, which 
cooperates with CtIP to catalyze the first step in DSB processing, short 
oligonucleotides are removed from the 5’ end. The short 3’ ssDNA 
tails formed after MRN-CtIP cleavage are subject to extensive 
resection in a second step execute via two parallel pathways 
determining 3’-ssDNA overhang. Single-stranded DNA generated by 
resection of the ends of a DSB provides a substrate for assembly of 
the Rad51 filaments needed for strand invasion; Rad51, a DNA-
dependent ATPase that forms nucleoprotein filaments with DNA, is a  
homolog of the bacterial RecA protein. Previous works observed that 
Single-stranded DNA within the RecA filament has a repeating unit of 
three nucleotides, which maintains a B-form structure. ATP hydrolysis 
promotes dissociation of the newly formed heteroduplex DNA and the 
displaced single strand. It is know that replication protein A (RPA) 
binds avidly to single-stranded DNA and effectively competes with 
Rad51, such that a number of proteins termed mediators are necessary 
to displace RPA to promote Rad51 binding, critical mediators are 
Rad52 in yeast and BRCA2 in mammalian cells, as Rad51 recruitment 
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to DSBs, and hence HR, are substantially impaired when these 
proteins are disrupted (Jasin & Rothstein, 2013).   
The resolution of such HR intermediate is carried out by a group of 
proteins called dissolvases or resolvases, which restore structural and 
molecular integrity of the DNA sequence, as described earlier on. 
Since inaccurate recombination or junction resolution may trigger  
chromosome aberrations, cells often repair DSBs by an alternative 
“recombination” pathway called single-stand annealing (SSA). This 
process is based on the RAD52 single-strand annealing activity for re-
sealing of the broken DNA-ends and does not require the RAD51 
strand-exchange activity. 
After replication fork stalling, RAD52 is recruited at perturbed forks 
to limit accessibility of fork remodeling factors, avoiding excessive 
fork reversal and inability of RAD51 to subsequently stabilize them. 
Later, RAD52 may also contribute to stabilization of RAD51 
filaments assembled at the reversed replication forks (Malacaria et al., 
submitted).  
In mitotic cell cycles, HR repair template usually comes from the 
homologous sequence on the sister chromatid. Moreover, molecular  
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intermediates of the recombination reaction, referred to as joint 
molecules (JMs), will form between the sister chromatids and link 
chromosomes, sometimes covalently (Holliday junctions), that can 
interfere with chromosome segregation. Hence, efficient JM 
disengagement and completion of HR are critical to prevent 
chromosome missegregation and thereby aneuploidy (Pfander & 
Matos, 2017). JMs that have matured to contain single or double 
Holliday junctions (HJs or dHJs, respectively) must be eliminated 
prior to mitosis to allow the equal distribution of DNA to the daughter 
cells(West et al., 2016; Wild & Matos, 2016). These activities can be 
subdivided into dissolution and resolution mechanisms. Dissolution 
involves the combined action of a helicase and a topoisomerase, both 
of which are located in a single protein complex called BTR (BLM-
TOPOIII alpha- RMI1-RMI2) in human cells and STR (Sgs1-Top3- 
Rmi1) in budding yeast. Mechanistically, dissolution works by first 
converting dHJs to hemicatenanes by the actions of the BLM/Sgs1 
helicase and the type IA topoisomerase TOPOIII alpha/Top3, 
followed by cleaving and resealing these hemicatenane structures by 
the activity of TOPOIII alpha/Top3 (Cejka, 2010; Chen et al., 2014; 
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Hickson, 2014). Due to the mechanism employed, STR and BTR are 
unable to ‘dissolve’ single HJs.  
The second principal mechanism of dHJ removal is resolution, which 
can operate on different JM structures, among them single HJs, and is 
catalyzed by structure-selective endonucleases, that cut HJs to 
produce crossover (CO) and non-crossover (NCO) products: MUS81- 
EME1 (Boddy et al., 2001), SLX4-SLX1(Wyatt, Sarbajna, Matos, & 
West, 2013) (Andersen et al., 2009; Fekairi et al., 2010; Wyatt et al., 
2013) and GEN1 (Ip et al., 2008) in human cells and Mus81-Mms4 
(Schwartz et al., 2012) and Yen1 (Ip et al., 2008) in budding yeast. All 
three nucleases belong to different protein families and are thought to 
resolve HJs by distinct – but sometimes cooperating – mechanisms 
(Pfander & Matos, 2017a). 
HJs processing can lead to the incidence of reciprocal genetic 
exchanges (cross- overs). Hence, if the template used for repair is the 
homologous chromosome, instead of the sister chromatid, loss of 
heterozygosity (LOH) can ensue. To suppress crossovers (COs), and 
the potential for LOH, proliferating cells dissolve most dHJs using the 
STR/ BTR pathway, which leads to formation of non-crossover 
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(NCO) recombinants, exclusively (Chen et al., 2001; Symington, 
2014).  
However, although the resolvases might have been originally 
considered as backup pathways for BTR, accumulating evidence 
demonstrating reduced survival of resolvase defective cells indicates 
that all three pathways are necessary for genome maintenance.  
Instead they should be thought of as essential factors that temporally 
regulated throughout the cell cycle most likely relates to the need to 
promote NCOs, rather than COs that could lead to a loss of 
heterozygosity and the ensuing dangerous elimination of tumor-
suppressor functions (Fig.6) (West et al., 2016).  
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Figure 6 Mechanisms for the processing of recombination intermediates in mitotic 
human cells. The two mechanisms involve (A)“dissolution” or (B) “resolution.” 
Dissolution is driven by the convergent migration of two Holliday junctions and 
topoisomerase- mediated dissolution of the resultant hemicatenane. The reaction 
involves BLM helicase, Topoisomerase IIIa, RMI1, and RMI2. Dissolution generates 
non-crossover products, thereby avoiding sister chromatid exchanges (SCEs) and the 
possibility for loss of heterozygosity (LOH) when recombination occurs between 
homologous chromosomes. Nucleolytic resolution is driven by two distinct pathways 
involving the SLX1-SLX4-MUS81-EME1 complex or GEN1 protein. Both generate 
crossovers and non-crossovers. (C, top panel) A high frequency of SCEs is observed 
in cells derived from individuals with Bloom’s syndrome (BS). (Lower panel) The 
elevated SCE frequency observed in BS cells is largely dependent on the resolution 
pathways, as observed by depletion ofSLX1 and GEN1 (West et al., 2016).  
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2 MUS81 
2.1 Structure and function  
The fission yeast and human MMS and UV-sensitive protein 81 
(MUS81)–essential meiotic endonuclease 1 (EME1) endonucleases 
(Boddy et al., 2001), is widely conserved amongst eukaryotes, 
including S. cerevisiae (Interthal & Heyer, 2000), S. pombe (Boddy et 
al., 2000), Arabidopsis thaliana (Hartung et al., 2006), mice, and 
human (Chen et al., 2001), but is absent in eubacteria. It is related to 
the XPF family of structure-specific endonucleases. XPF family 
members typically contain a pair of helix-hairpin-helix (HhH) motifs, 
and a conserved catalytic domain in their C-terminal region with an 
ERKX3D active site motif (Fig. 7). In MUS81 the HhH motifs are 
positioned at either end of the protein, whereas in XPF they occur 
tandemly at the C-terminal end. The HhH motifs probably promote 
dimer formation and DNA binding, and are required for nuclease 
activity. They may also play a role in substrate recognition by 
engaging the DNA duplexes on either side of a nick or 3’-flap 
(Newman et al., 2005). Eukaryotic XPFs function as heterodimers 
with a non-catalytic partner protein (ERCC1 in humans, Rad10 in  
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budding yeast, and Swi10 in fission yeast) that is important for their 
stability and nuclease activity, and may also play a part in substrate 
recognition. Likewise Mus81 has a partner (Eme1 in fission yeast and 
humans, and Mms4 in budding yeast) that is essential for its 
endonuclease activity (Abraham et al., 2003; Boddy et al., 2001; 
Kaliraman et al., 2001; Sancar, 2003). By analogy to XPF-ERCC1 it 
has been assumed that Mus81-Eme1/Mms4 functions as a 
heterodimer. However, the individual subunits can self-associate and 
higher molecular weight complexes have been seen by gel filtration 
(Blais et al., 2004; Fricke et al., 2005).  
Figure7 The domain 
structure of Mus81 
and Eme1, and their 
relationship to XPF 
and ERCC1 (Osman 
and Whitby 2007). 
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The in vitro substrate specificity of MUS81 complex 
Despite their relatedness, biochemical and genetic evidence indicates 
that MUS81/EME1 and eukaryotic XPF proteins play distinct roles in 
DNA metabolism (Bastin-Shanower et al, 2003; Boddy et al., 2000). 
The enzymes have different substrate specificity, and double mutant 
analysis indicates that they function in separate pathways. 
Furthermore, whereas XPF exhibits some sequence-dependence for 
cleavage, the same is not true for MUS8/EME1. The main role of XPF 
in eukaryotic cells is in nucleotide excision repair where it makes the 
incision 5’ to the DNA lesion. In contrast, several lines of evidence 
suggest that in mitotic cells MUS81 processes replication and 
recombination-associated DNA structures that form when RFs stall or 
collapse (Whitby et al., 2003). In vitro MUS81/EME1 has been shown 
to cleave a number of synthetic DNA structures that are designed to 
mimic potential in vivo substrates.  
From such studies, the view has emerged that the preferred substrates 
for MUS81/EME1 are three- and four- way junctions that, in contrast 
to eukaryotic XPF’s preferred substrates, have an exposed 5’-DNA 
end, at or close to the junction point,  that activates and directs  
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cleavage (Bastin-Shanower et al., 2003; Fricke et al., 2005; Whitby et 
al., 2003). Examples of these preferred substrates are nicked HJs, D-
loops, RFs with the lagging strand at the junction point, and 3’-flaps 
(Fig. 8). 
 
 
 
 
 
 
 
Figure 8 The substrate specificity of Mus81/Eme1. The arrows indicate Mus81 
cleavage sites (Osman & Whitby, 2007). 
2.3 Controlling structure-selective endonucleases MUS81 complex 
In S. cerevisiae, a complex of Mus81 and the EME1 orthologue 
methyl methanesulfonate sensitivity protein 4 (Mms4) is upregulated 
in mitosis through phosphorylation of Mms4 by the yeast orthologues  
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of mammalian cyclin-dependent kinase 1 (CDK1) and Polo-like 
kinase 1 (PLK1), Cdc28 and Cdc5, respectively (Gallo-Fernández et 
al., 2012; Matos et al., 2011; Szakal & Branzei, 2013) (Fig.9a). In 
Schizosaccharomyces pombe, upregulation of Mus81– Eme1 is 
instead triggered by DNA damage through a mechanism in which 
Cdc28-dependent phosphorylation of Eme1 primes the protein for 
additional phosphorylation by Rad3 (ataxia telangiectasia and Rad3-
related protein (ATR) in metazoans) (Dehé et al., 2013) (Fig. 9b). This 
different mode of regulation may reflect the fact that S. pombe lacks a 
GEN1 nuclease and relies mainly on Mus81– Eme1 for the processing 
of Holliday junctions (Copsey et al., 2013; Wehrkamp-Richter et al., 
2012). In human cells, MUS81–EME1 activity peaks in M phase, and 
this correlates with the hyper phosphorylation of EME1 by CDK1 and 
PLK1 and an increased association with the scaffold protein SLX4, 
which has been shown to stimulate MUS81–EME1 in vitro and 
coordinates the resolution of Holliday junctions by MUS81–EME1 
and SLX1 (Castor et al., 2013; Wyatt et al., 2013) (Fig.9c). Optimal 
processing of Holliday junctions in meiosis and mitosis is carried out 
by the MUS81–EME1 and GEN1 resolvases (Blanco & Matos, 2015;  
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Matos & West, 2014). Upregulation of GEN1 in human cells and its 
orthologue crossover junction endodeoxyribonuclease 1 (Yen1) in S. 
cerevisiae occurs later in mitosis, at a time that is considered the last 
point at which Holliday junctions can be resolved before chromosome 
segregation. Phosphorylation controls both the catalytic activity of 
Yen1 and its localization, by inactivating its nuclear localization signal 
and thereby retaining the protein in the cytoplasm. In human cells, 
control of GEN1 is independent of phosphorylation and instead relies 
entirely on a nuclear export signal that prevents GEN1 from accessing 
chromosomes until nuclear envelope breakdown occurs in mitosis 
(Chan et al.,  2014) (Fig.9c).  
Of note, Yen1 has an additional function in S. cerevisiae — in the 
response to replication stress — that is distinct from its canonical 
Holliday junction resolvase activity, although this is still regulated by 
the cell cycle (Ölmezer et al., 2016). The timely upregulation of 
Holliday junction resolvases in late G2 and M phase ensures optimal 
processing of Holliday junctions before chromosome segregation. A 
current view is that it also provides time for double Holliday junctions 
to be removed by the combined action of the RecQ-like helicase  
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Bloom syndrome protein (BLM) in humans (Kowalczykowski, 2015). 
BLM promotes the partial disassembly of the replisome (Shimura et 
al., 2008), which may be a prerequisite for MUS81 to process 
replication intermediates. BLM can also directly associate with 
MUS81 and enhance its endonucleolytic activity (Ran et al., 2005), 
thereby potentially contributing directly to the formation of MUS81-
mediated DSBs at perturbed replication forks. Another RecQ DNA 
helicases, WRN (Werner syndrome (WS) has been proposed to reset 
reversed forks or other replication intermediates arising after fork 
stalling, clearing the way to replisome progression once the block is 
removed (Khakhar et al., 2003). Alternatively, WRN has been 
implicated in the resolution of recombination intermediates arising 
after RAD51- dependent strand invasion (Saintigny et al., 2002). Cells 
mutated in WRN accumulate DNA breaks if challenged with 
replication-perturbing agents, which is indicative of incorrect handling 
of stalled forks (Pichierri et al., 2001). In yeasts, mutations of the 
RecQ helicase Sgs1 or Rqh1 are synthetic lethal with mutations in 
MUS81 (Boddy et al., 2000; Kaliraman et al., 2001; Mullen et al., 
2001).  
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The observation that mutation in MUS81 reduces viability of RecQ-
defective yeasts after fork stalling suggested that these two proteins 
might function on common substrates in response to replication stress, 
defining two parallel branches of the replication fork recovery 
pathway. Franchitto et al. demonstrate that in WRN-deficient cells, the 
MUS81 endonuclease represents an alternative pathway to ensure 
recovery of DNA synthesis by recombination-mediated restart of 
DNA replication (Franchitto et al., 2008). 
 
Figure 9 Controlling the processing of Holliday junctions by structure- specific 
endonucleases. (a) In Saccharomyces cerevisiae, efficient processing of Holliday 
junctions during late G2 and mitosis relies on the timely activation of both MMS and 
UV-sensitive protein 81 (Mus81)–methane methyl sulfonate- sensitive protein 4 
(Mms4) and crossover junction endodeoxyribonuclease 1 (Yen1) through cycles of 
phosphorylation (P) and dephosphorylation. (b) In contrast to the cell cycle-dependent 
activation of Mus81–Mms4, upregulation of Mus81–essential meiotic endonuclease 
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1 (Eme1) activity in Schizosaccharomyces pombe occurs in response to DNA 
damage. Cdc2-mediated phosphorylation primes Eme1for DNA damage-induced 
phosphorylation by radiation-sensitive mutant 3 (Rad3). The sequential 
phosphorylation of Eme1 restricts the catalytic upregulation of Mus81–Eme1 to G2 
and only when the DNA damage checkpoint is activated. (c)  In human cells, cell 
cycle-dependent phosphorylation of EME1 by cyclin-dependent kinase 1 (CDK1) and 
Polo-like kinase 1 (PLK1) correlates with increased Holliday junction resolvase 
activity of MUS81– EME1 it also promotes interaction of MUS81–EME1 with 
SLX4–SLX1 Holliday junction resolvase. Control of GEN1 is independent of 
phosphorylation, but instead relies entirely on a nuclear export signal (NES) that 
prevents GEN1 from accessing chromosomes until breakdown of the nuclear 
envelope in mitosis (Dehé and Gaillard, 2017). 
2.3.1 MUS81 contributes to DNA damage response  
The fact that MUS81–EME1 is upregulated at the onset of mitosis, 
together with accumulating evidence of the deleterious actions of 
MUS81 in S phase under specific circumstances, suggests that MUS81 
is kept away from replication forks. However, cells that lack 
functional MUS81 are hypersensitive to DNA-damaging agents that 
impede replication fork progression (Franchitto et al., 2008). The 
catalytic activity of MUS81–EME1 can be enhanced by different 
partners of MUS81, which suggests that a complex regulatory network  
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exists, that may involve fine-tuning of the nuclease, even in S phase. 
There is strong evidence that MUS81-dependent enzymes are needed 
during S phase in human cells. Early reports found that MUS81 levels 
peak in S phase — with a marked accumulation in the nucleolus — 
consistent with a role for MUS81 in the maintenance of rDNA loci, 
which are prone to replication stress (Gao Hui, Xiao-Bo Chen, 2003). 
Furthermore, MUS81 is needed for replication fork restart following 
treatment with the replication inhibitors hydroxyurea, camptothecin or 
aphidicolin (low levels) in human or mouse embryonic stem cells 
(Hanada et al. 2007; Regairaz et al. 2011; Pepe and West 2014; Fu et 
al. 2015; Palma, Pugliese et al., 2018).   
Despite the evidence that MUS81 has a positive role in DNA 
replication, very little is known about how its functions in S phase are 
regulated, and most of what is known relates to negative regulatory 
processes that prevent the opportunistic action of MUS81 nucleases 
on replication intermediates. The S phase checkpoint is crucial for 
preventing any uncontrolled and deleterious action of MUS81 
nucleases in response to sustained replication stress. In S. pombe, the 
regulation of Mus81–Eme1 in S phase relies on the phosphorylation  
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of Mus81 by the kinase checkpoint DNA synthesis protein 1 (Cds1) in 
response to replication stress (Boddy et al., 2000). Strong activation 
of Cds1 in response to acute hydroxyurea treatment leads to the 
dissociation of Mus81 from chromatin and prevents extensive 
cleavage of replication intermediates and cell death (Froget et al., 
2008; Kai et al., 2005). However, Mus81 is necessary for surviving 
chronic hydroxyurea treatment. Of note, the interaction of Mus81 with 
the forkhead-associated domain (FHA domain) of Cds1 is conserved 
in human cells, in which MUS81 interacts with the ATM effector 
checkpoint kinase 2 (CHK2; also known as CHEK2) (Chen et al., 
2001); however, it is unclear whether MUS81 is directly regulated by 
CHK2 (and object of our laboratory investigation). Identifying which 
component in the endogenous Mus81–Mms4 complex prevents the 
efficient processing of these structures may help further the 
understanding of how Mus81 nucleases are controlled in S phase. 
Direct negative regulation of human MUS81 by the checkpoint kinase 
WEE1, which binds and phosphorylates MUS81, are proposed on the 
basis that inhibition of WEE1 results in DNA damage that is alleviated 
by depleting MUS81. A non-mutually exclusive alternative is that  
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WEE1 curtails replication stress by keeping CDK activity low, thereby 
preventing uncontrolled firing of replication origins and a shortage of 
deoxynucleoside triphosphates and replication factors. 
Importantly, although depletion of MUS81 prevents DSB formation 
following depletion of WEE1, it does not prevent the activation of 
ATR, which suggests that MUS81 acts downstream of replication fork 
stalling and S phase checkpoint activation (Beck et al., 2012). This is 
consistent with the deleterious processing of replication intermediates 
by MUS81–EME1 (Forment et al., 2011; Murfuni et al., 2013) or by 
MUS81–EME2 and MRE11, which occurs following the inhibition of 
the ATR effector CHK1.  
MUS81–EME2-mediated DNA damage is proposed to result from 
premature activation of the complex by increased levels of CDK2 
(Técher et al., 2016); however, in contrast to the CDK1- and PLK1-
mediated upregulation of MUS81–EME1 activity, little is known 
about the control of MUS81–EME2. What we know is that EME1 
interacts with MUS81 throughout the cell cycle, as the interaction 
between MUS81 and EME2 occurs predominantly during S phase. 
Preliminary studies in vitro showed that MUS81-EME2 was more  
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active than MUS81- EME1, and it preferentially cleaved 3’-flaps and 
RFs, whereas the nicked HJ was the preferred substrate for MUS81-
EME1 (Fig.10) (Pepe & West, 2014). Such How the formation of the 
MUS81-EME2 complex is prevented during G2 and M phase is 
presently unknown (Pepe & West, 2014) and will be the subject of 
future study. Moreover, understanding how this complex is regulated 
is important, given that MUS81–EME2 is the prime culprit 
responsible for the DNA damage that results from the premature entry 
into mitosis that is induced by inhibition of WEE1 (Duda et al., 2016). 
 
 
Figure 10 Association of MUS81 
with EME1 or EME2 during cell 
cycle (Pepe and West, 2014). 
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In addition to preventing catalytic upregulation of MUS81 nucleases, 
the S phase checkpoint is also needed to prevent their premature 
association with SLX4, which is present at replication forks (Ohouo 
et al., 2010; Princz et al., 2015). In human cells, MUS81–EME1 
normally associates with SLX4 in late G2 and M phase, following the 
phosphorylation of EME1 by CDK1 and PLK1 and of SLX4 by CDK1 
(Duda, et al., 2016). Increased recruitment of MUS81 to chromatin is 
seen shortly after inhibition of WEE1 and the resulting formation of 
DSBs is also reduced by SLX4 depletion(Beck et al., 2012; Duda et 
al., 2016). The tumour suppressor SLX4 has attracted considerable 
attention in recent years after it was found to associate in human cells 
with XPF–ERCC1, MUS81– EME1 and SLX1 (Andersen et al., 2009; 
Muñoz et al., 2009). SLX4 stimulates the catalytic activity of all three 
nucleases (Fekairi et al., 2010; Muñoz et al., 2009; Svendsen et al., 
2010a) and it has a pivotal role in channelling them into specific 
genome maintenance pathways and in their timely recruitment to 
DNA lesions and/or specific genomic loci.  
It was recently showed that Human SLX4 provides the scaffold for a 
tri-nuclease complex called SMX, comprised of SLX1-SLX4,  
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MUS81-EME1, and XPF-ERCC1. Human SMX is the only known 
example of a tri-nuclease complex (Wyatt & West, 2017). SMX was 
found to be a promiscuous endonuclease that cleaves a broad range of 
DNA secondary structures in vitro. It was also shown that SLX4 
activates MUS81-EME1 to cleave structures that resemble stalled 
replication forks (Fig. 11) (Wyatt et al., 2017). Activation involves 
relaxation of MUS81-EME1’s substrate specificity, which is regulated 
by a helix-hairpin-helix (HhH) domain in the MUS81 N-terminus 
(MUS81 N-HhH). Intriguingly, MUS81 N-HhH also mediates the 
interaction with SLX4 via a C-terminal SAP domain (SLX4 SAP) 
(Nair et al., 2014). Therefore, SMX provides an efficient tool to 
remove various DNA structures that would otherwise impede DNA 
replication and/or chromosome segregation. This proposal is 
supported by data showing that SMX-mediated cleavage of CFSs is 
necessary for genome stability (Minocherhomji et al., 2015b). 
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Figure 11 Cell cycle-regulated formation of the SMX tri-nuclease. The MUS81-
EME1 subunit is recruited to a sub-complex comprised of SLX1-SLX4 and XPF-
ERCC1 at a late phase of the cell-cycle, leading to the formation of SMX. 
Recombinant SMX cleaves a broad range of branched DNA structures (e.g. stalled 
replication forks, late replication intermediates, Holliday junctions) that would 
interfere with replication and/or chromosome segregation in the cell. The nucleases 
responsible for DNA cleavage depend on the DNA structure: MUS81-EME1 and 
SLX1 are required for coordinated Holliday junction resolution whereas MUS81-
EME1 is activated to cleave replication-related structures (Wyatt & West, 2017).  
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As mentioned above, DNA damage-induced recruitment of MUS81–
EME1 to CFSs, and the activation of the complex by hyper 
phosphorylation of EME1 at the very late G2-phase of the cell cycle, 
suggests that cells may be unable to detect replication problems at 
specific loci and also fail to activate a checkpoint response before 
entry into mitosis (Dehé et al., 2013; Ying et al., 2013). When cells 
are treated with mild doses of APH, particular Fanconi anemia 
proteins, including FANCD2 and FANCI, are specifically recruited to 
CFS loci in the genome(Chan et al., 2007).  DNA replication or repair 
intermediates at CFSs that escape the attention of MUS81–EME1 
during early mitosis manifest as unresolved DNA bridges in anaphase 
(Ying et al., 2013a). The SNF2-family translocase PICH (also known 
as ERCC6L) and the BTRR complex colocalize on these bulky bridges 
and UFBs during anaphase (Baumann et al., 2007; Chan et al., 2007). 
Failure to separate sister chromatids faithfully during anaphase can 
result in chromatin segregation defects, and possibly also 
chromosome-shattering (so called chromothripsis), resulting in an 
increased incidence of chromosomal rearrangements and micronuclei 
in subsequent G1 daughter cells (Crasta et al., 2012; Holland &  
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Cleveland, 2012).  Following MUS81 depletion, an increase in the 
numbers of DAPI-positive chromosome-bulky bridges, micronuclei, 
and FANCD2-associated UFBs was observed in anaphase, suggesting 
that failure to cleave the CFS locus leads to an elevation in 
chromosome nondisjunction events associated with the failed 
segregation of sister chromatids (Fig. 12). Moreover, an increase in 
the number of CFS-associated 53BP1 nuclear bodies (Lukas et al., 
2011) in newly formed G1 daughter cells is seen in MUS81-depleted 
cells, representing the transmission of replication errors from the 
previous cell cycle (Naim et al., 2013; Ying et al., 2013). 
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Figure 12 Model representing the molecular events leading up to common fragile site 
expression. Model showing that MUS81-dependent cleavage is required for the 
generation of breaks or gaps at common fragile site (CFS) loci, which are marked by 
the recruitment of a FANCD2 (Fanconi anemia group D2 protein) focus on each 
segregating sister chromatid in mitosis. FANCD2 foci associate with CFS loci 
throughout G2 and mitosis. The upper panel (+MUS81–EME1) shows normal cells, 
and the lower panel (MUS81–EME1) shows the situation in cells lacking MUS81–
EME1. Depletion of MUS81 results in a reduction in the incidence of breaks or gaps 
at CFS loci, promoting the occurrence of CFS-associated sister chromatid non-
disjunction. CFS loci that are not cleaved by MUS81 in early mitosis persist as bulky 
anaphase bridges or ultra-fine anaphase DNA bridges (UFBs) marked by FANCD2 
foci at their termini, which are then processed by the Bloom’s syndrome helicase BLM 
and the PICH (Plk1- interacting checkpoint helicase) translocase in anaphase.  
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This permits cell division to take place, albeit with structural abnormalities that 
manifest as an increased frequency of CFS-associated, PICH-positive micronuclei in 
G1-daughter cells. In addition, the DNA repair factor 53BP1 forms nuclear bodies in 
G1 cells, potentially ‘shielding’ CFS regions (Minocherhomji & Hickson, 2014). 
Most recently, it was observed that RAD52 is important for 
homology-directed DNA repair and has been found to promote 
MUS81 recruitment to persistent replication intermediates, without 
interfering with the localization of SLX4 (Bhowmick 2016b; Sotiriou 
et al., 2016). Murfuni et al. demonstrates the cooperation between 
RAD52 and MUS81 in response to replication stress; briefly RAD52, 
through its ssDNA annealing activity, produce a D-loop intermediate 
and possibly helps recruiting MUS81/EME1 complex by protein-
protein interaction. The flap intermediate is targeted by MUS81 
resulting in DSBs and fork collapse. In the absence of a functional 
checkpoint (i.e. inactive CHK1), the RAD52-dependent pathway is a 
favourite way of ensuring proliferation at the expense of genome 
stability (Murfuni et al., 2013a). Replication fork stalling at genomic 
regions that are difficult to replicate or contain endogenous DNA 
lesions is a hallmark of BRCA2 deficiency (Lai et al., 2017). BRCA2 
plays essential roles both in the protection of the stalled replication 
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forks by preventing their nucleolytic degradation (Schlacher et al, 
2011) and in fork restart through RAD51-mediated reactions (Roy et 
al., 2016). Recently, it has been reported that MUS81 facilitates DNA 
replication not only upon treatment with drugs that interfere with DNA 
replic1ation (Hanada et al., 2007; Sarbajna et al., 2014; Ying et al., 
2013b), but also in the absence of exogenous damage (Fu et al., 2015). 
Most recently, it was demonstrated on one side a dual cell-cycle 
dependent role of MUS81 to sustain replication fork progression in 
BRCA2-deficient cells through mechanisms distinct from the restart 
of stalled replication forks. Lemaçon and coworkers have shown that 
MUS81-dependent cleavage of the resected forks is required for fork 
restart in BRCA2-deficient cells through a break-induced replication 
(BIR)-like mechanism mediated by POLD3-dependent DNA 
synthesis. They also proposed that MUS81 acts downstream of 
MRE11- and EXO1-mediated degradation (Lemaçon et al., 2017a).  
On the other, Lai and coworkers have demonstrated that loss of 
MUS81 triggers increased replication stress and reduced survival in 
BRCA2-deficient cells. These cells progress into mitosis with 
incompletely replicated DNA, visualized as multiple chromosome 
interlinks in anaphase.  
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Moreover, BRCA2-deficient cells rely on MUS81 to continue DNA 
synthesis during mitosis, the absence of which causes severe 
chromosome segregation defects and G1 arrest. Moreover, in cells 
lacking BRCA2, MUS81-dependent nucleolytic cleavage removes 
DNA bridges caused by under-replicated DNA and provides a 
mechanism to complete replication in mitosis. MUS81 provides a 
mechanism of replication stress tolerance that sustains proliferation 
and survival of BRCA2-deficient cells. In cancer cells lacking 
BRCA2, dysfunctional checkpoints, including SAC failure, enable  
mitotic entry and progression with incompletely replicated genomes. 
Thus, BRCA2-deficient cells rely on MUS81 not only to reduce the 
replication stress burden during S phase, but also to eliminate the 
detrimental consequences of under-replicated DNA during mitosis 
(Fig.13) (Lai et al., 2017).  In the second part of my elaborate, I wanted 
to investigate the role of phosphorylation on S87 residue of MUS81 in 
BRCA2-deficient cells in sustaining replication fork progression and 
viability during unchallenged DNA replication. 
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Figure 13Model for concerted action of MUS81 and BRCA2 during mitosis. BRCA2-
proficient cells require MUS81 for cleavage of UFBs formed during mitosis at under-
replicated CFS. In cells lacking BRCA2, incomplete DNA replication at multiple sites 
leads to DAPI-stained bridges detectable in anaphase as chromosome interlinks. 
MUS81 is required to resolve these bridges and to promote mitotic DNA synthesis, 
ultimately facilitating chromosome segregation. MUS81 inactivation in BRCA2-
deficient cells leads to persistent chromosome interlinks, multinucleation, 
supernumerary centrosomes and cell death. Blue, sister chromatids; yellow, 
centrosomes; light blue, microtubules (Lai et al., 2017). 
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2.4 Cell cycle regulation  
Cells need to recruit safely these potentially damaging endonucleases 
to DNA only at specific time-points of the cell cycle, and regulate their 
controlled ‘activation’ in response to DNA damage (Minocherhomji 
& Hickson, 2014).  
Budding yeast Mus81 forms a constitutive dimer with Mms4, which 
is phosphorylated at the G2/M Transition (Ehmsen & Heyer, 2008; 
Gallo-Fernández, 2012; Matos, 2011; Matos, 2013; Szakal & Branzei, 
2013). Phosphorylation of Mms4 in mitosis leads to an upregulation 
of the catalytic activity of Mus81-Mms4, which is crucial for timely 
resolution of JMs before chromosome segregation. The mitotic 
phosphorylation of Mms4 was initially found to require Cyclin-
dependent kinase (Cdc28, Cdk1) and the Polo-like kinase Cdc5. 
Recent work identified a third cell cycle kinase targeting Mms4 – the 
Dbf4- dependent kinase DDK.  Importantly, however, Mus81 
activation is diminished in the absence of any of the three cell cycle 
kinases (Princz et al., 2017).  
Following the initial work in yeast, studies carried out in human cells 
indicate that similar principles operate to regulate MUS81 function  
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(Duda et al., 2016; Matos et al., 2011; Wyatt et al., 2013). EME1 is 
phosphorylated in a CDK1-dependent manner at the G2/M transition. 
Several studies suggest that human cells rely on an alternative 
molecular strategy to boost the ability of MUS81 to process HJs: 
CDK1-mediated phosphorylation promotes MUS81-EME1 
association with SLX1-SLX4 to form the SLX-MUS complex (Castor 
et al., 2013; Garner, 2013; Wyatt et al., 2017, 2013) (Fig. 14).  
How CDK1 activity enhances the ability of MUS81 to interact with 
SLX4 has yet to be determined. However, MUS81 and SLX4 are 
phosphorylated in a CDK1-dependent and cell cycle stage-specific 
manner, alongside EME1, suggesting that their modification might 
stabilize the SLX-MUS complex (Duda et al., 2016; Wyatt et al., 
2013). Hence, to efficiently resolve replication intermediates during 
mitosis, MUS81 function is likely to require SLX4 for two reasons: 
(a) recruitment to sites of stalled replication and (b) modulation of the 
nuclease activity through relaxation in substrate specificity. It will be 
interesting to determine if SLX4 also changes the properties of 
MUS81-EME2 nuclease using in vitro approaches and to investigate 
whether anti-EME1 or EME2 immunoprecipitates display different 
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profiles of RF cleavage throughout the cell cycle (Pfander & Matos, 
2017a).  
Another cell cycle kinase, WEE1, has also been implicated in the 
regulation of MUS81 in human cells. However, in contrast to CDK1 
and PLK1, WEE1 was found to suppress MUS81 function (Beck et 
al., 2012; Domínguez-kelly et al., 2011; Duda et al., 2016) and 
prevents excessive origin firing and replication stress by limiting 
CDK2 activity during S-phase, which may lead to formation of 
aberrant replication intermediates that become MUS81 targets (Beck 
et al., 2012; Domínguez-kelly et al., 2011). Recent work revealed 
another key role of WEE1 in suppressing MUS81 function. By 
restraining CDK1 activity in S-phase, WEE1 indirectly prevents 
unscheduled SLX4 phosphorylation and premature SLX-MUS 
complex formation. This precludes widespread recruitment of MUS81 
nuclease to replication intermediates and, ultimately, avoids 
chromosome pulverization. Consistent with this notion, inhibition of 
CDK1 restores bulk DNA replication and suppresses the shredding of 
chromosomes caused by WEE1 inhibition. One surprising finding 
arising from the analysis of chromosome breakage upon inhibition of 
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WEE1 was its exquisite dependency on EME2, making us think that 
MUS81-EME2 requires especially tight control (Duda et al., 2016). 
 
 
Figure 14 Mechanisms of Mus81 regulation. In budding yeast, cell cycle kinases 
phosphorylate Mms4 to enhance the nuclease activity of Mus81-Mms4 (1). The 
scaffold protein Rtt107 indirectly enhances Mus81 activity by promoting Mms4 
phosphorylation (2). It is unknown if the Slx4 scaffold regulates Mus81 activity 
through direct binding (3) or through spatial coordination of the activities of Mus81 
and Slx1 (4). Dpb11 and Rtt107 may regulate Mus81 recruitment to substrates (5). In 
human cells, binding to the SLX4 scaffold relaxes and enhances the nuclease activity 
of MUS81 in vitro (3), coordinates MUS81 and SLX1 for Holliday junction resolution 
(4), interacts with TOPBP1 and is required for substrate targeting in vivo (5). The 
regulatory subunit EME1 (if EME2 is also phosphorylated in vivo is unknown) is 
phosphorylated in a cell cycle stage-specific manner (1), but the role of this 
modification is unknown (Pfander and Matos 2017). 
64 
 
Additional factors operate downstream of or in parallel to SLX4 in 
controlling MUS81. SMC2, which is required for chromosome 
condensation, WAPL and PLK1, which are necessary for the release 
of sister- chromatid arm cohesion in early mitosis, were shown to 
promote MUS81 recruitment to sites of stalled replication, without 
interfering with the recruitment of SLX4.  
Precisely how these factors contribute to MUS81 recruitment remains 
unclear (Minocherhomji et al., 2015).  
Despite the many results obtained about the cell cycle control of the 
MUS81 nuclease it will be extremely interesting to learn more about 
how cells control MUS81 function. This leaded us to a question:  Does 
MUS81 phosphorylation control its function? It is likely that the 
MUS81 undergoes cell-cycle-specific phosphorylation events that 
may contribute to tightly regulate its function together with the 
observed modification of the EME1/2 subunit. 
In fact, although signs of phosphorylation induced changes in the 
electrophoretic mobility of EME1 and EME2 are apparent (Pepe & 
West, 2014a), little if any information exist on phosphorylation of the 
MUS81 subunit and its possible functional relevance.  
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However, phosphorylation of the invariant subunit of the two 
MUS81/EME complexes could be a more efficient way to regulate 
activity of the holoenzyme, as well as association with proteins that 
can influence its biological activity under normal or pathological 
conditions (Fekairi et al., 2010; Franchitto et al., 2008; Pepe & West, 
2014a; Sarbajna & West, 2014). In addition to mentioned kinases an 
attractive one for the regulation of MUS81 complex is the pleiotropic 
CK2 (Franchin et al., 2017; Meggio & Pinna, 2003). Indeed, CK2 is 
important to regulate mitotic progression, is activated by CDK1 and 
phosphorylates several repair/recombination enzymes, such as 
MDC1, MRE11 and RAD51 (Chapman & Jackson, 2008; Kim, 2005; 
Meggio & Pinna, 2003; Spycher et al., 2008; Strauss et al., 2018). 
Protein kinase CK2 is a serine/threonine kinase highly conserved 
throughout evolution and is ubiquitously expressed in eukaryotic cells. 
Traditionally, CK2 is described as a constitutively active tetrameric 
enzyme composed of two catalytic α and/or α’ subunits and two 
regulatory β subunits. CK2 is involved in various intracellular 
processes ranging from regulation of transcription and DNA 
replication to proliferation, survival and differentiation. Evidence that  
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CK2 plays a role in cell-cycle regulation in mammalian cells comes 
from findings that CK2 is associated with the mitotic spindle and 
centrosomes and interacts with and/or phosphorylates numerous cell- 
cycle regulatory proteins including Pin1, topoisomerase II, cdc34 and 
CDK1 (Yde et al. , 2008).  
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MATERIALS AND METHODS  
In vitro kinase assay 
For in vitro kinase assays, 300ng or 2μg (MS/MS) of the indicated 
GST-fused MUS81 fragments were incubated with recombinant 
purified CK2 (NEB), kinase in the presence of 32P-ATP, or ATP, and 
in kinase-specific reaction buffer prepared according to the 
manufacturers’ directions. After washing, GST-fragments were 
released and analysed as previously reported (Ammazzalorso et al., 
2010). Caseins (Sigma-Aldrich) were used as positive control in the 
CK2 kinase assay. For the full-length assay, 200ng of full-lenght 
MUS81 immunopurified from HEK293T cells (Origene) was 
incubated with 200ng of CK2 kinase. Phosphorylation was analysed 
by SDS-PAGE and WB. 
Cell culture, generation of cell lines and RNA interference 
The SV40-transformed MRC5 fibroblast cell line (MRC5SV40) was 
a generous gift from Dr. P. Kannouche (IGR, Villejuif, France). 
HEK293T cells line were obtained from American Type Culture 
Collection (VA, USA). The cells were maintained in Dulbecco’s 
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modified Eagle’s medium (DMEM; Life Technologies) supplemented 
with 10% FBS (Boehringer Mannheim) and incubated at 37 °C in a 
humidified 5% CO2 atmosphere. Cell line were routinely tested for 
mycoplasma contamination and maintained in cultures for no more 
than one month. 
To obtain the MRC5shMUS81 cells or the shMUS81-HEK293T cells, 
a retroviral plasmid containing an MUS81-targeting shRNA sequence 
(Origene cod. TR303095, sequence #1) was nucleofected using the 
Neon system (Life technologies). Three days after nucleofection, cells 
were subjected to selection with 500ng/ml puromycin and resistant 
clones expanded, tested for MUS81 depletion and phenotype before 
further use. To complement MRC5 shMUS81 cells with the wildtype 
MUS81 or its phosphomutants, the wild type form of MUS81 ORF 
cloned into the pCMVTag2B plasmid was subjected to SDM 
(Quickchange II XL – Stratagene) to introduce the S87A or S87D 
mutations. After the first round of mutagenesis, all MUS81 ORFs were 
made RNAi-resistant by SDM, sequence-verified and cloned into 
pEF1a-IRES-NEO vector by the Gibson Assembly protocol (NEB). 
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Sequence-verified plasmids were then transfected into MRC5 
shMUS81 cells by the Neon nucleofector (Life technologies) in order 
to obtain cell lines stably expressing MUS81 and its mutant forms. 
Cell colonies were selected by 1mg/ml G418 antibiotic (Santa Cruz 
Biotechnologies). RNA interference against MUS81 was performed 
as previously reported(Ivana Murfuni et al., 2013a) For BRCA2 
interference were used   . In all experiments, cells were transfected 
using Lullaby (OZ Biosciences). RNA interference against EME2 was 
performed with siRNA-SMART pool, 10nmol (197342) from 
Dharmacon and against BRCA2 with siRNA-FlexiTube, 5nmol 
(1027417) from Qiagen. The efficiency of protein depletion was 
monitored by western blotting 48-72h after transfection.  
Chemicals 
Hydroxyurea (Sigma-Aldrich) was used at 2 mM, the DNA replication 
inhibitor aphidicolin (APH) (Sigma-Aldrich) was used at 0.2 μM (low 
dose) or 1.5 μM (intermediate dose). The CK2 inhibitor CX4925 
(Selleck chemicals) was used at 25 μM, the CDK1 inhibitor (RO-
3306, Sigma-Aldrich) at 9 μM and WEE1 inhibitor (MK-1775, 
Selleck chemicals) was used at 500 μM. The L67 inhibitor of human 
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DNA ligase I and II (Axon Medchem) was used at 0.5 μM. 
Nocodazole (Sigma- Aldrich) was used at 0.5 μg/μl and Thymidine 
(Sigma-Aldrich) at 2 mM. 5-Bromo-2´-Deoxyuridine (BrdU, Sigma-
Aldrich) was used at 30 μM. 
Neutral Comet assay 
DNA breakage induction was evaluated by Comet assay (single cell 
gel electrophoresis) in non-denaturing conditions as described in 
Murfuni et al. Briefly, dust-free frosted-end microscope slides were 
kept in methanol overnight to remove fatty residues. Slides were then 
dipped into molten Low Melting Point (LMP) agarose at 0.5% and left 
to dry. Cell pellets were resuspended in PBS and kept on ice to inhibit 
DNA repair. Cell suspensions were rapidly mixed with LMP agarose 
at 0.5% kept at 37 °C and an aliquot was pipetted onto agarose-
covered surface of the slide. Agarose embedded cells were lysed by 
submerging slides in lysis solution (30 mM EDTA, 0,1% SDS) and 
incubated at 4 °C, 1 h in the dark. After lysis, slides were washed in 
TBE 1X run- ning buffer (Tris 90 mM; boric acid 90 mM; EDTA 4 
mM) for 1 min. Electrophoresis was performed for 20 min in TBE 1X 
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buffer at 0.5 V/cm. Slides were subsequently washed in distilled H2O 
and finally dehydrated in ice cold methanol. Nuclei were stained with 
GelRed (1:1000) and visualized with a fluorescence microscope 
(Zeiss), using a 60X objective, connected to a CCD camera for image 
acquisition. At least 300 comets per cell line were analyzed using 
CometAssay IV software (Perceptive instruments) and data from tail 
moments processed using Prism software. Apoptotic cells (smaller 
Comethead and extremely larger Comettail) were excluded from the 
analysis to avoid artificial enhancement of the tail moment. A 
minimum of 200 cells was analyzed for each experimental point. 
Immunoprecipitation and Western blot analysis 
Immunoprecipitation experiments are performed using 2.5 106 cells. 
The cell pellets were resuspended in lysis co-IP buffer (1% Triton X-
100, 0.5% Na-dehoxycolate, 150 mM NaCl, 1 mM EGTA, 20 mM 
Tris/HCl pH 8.0), freshly supplemented with protease inhibitor 
cocktail and benzonase was used for cells lysis. After centrifugation, 
for each IP sample, lysate was incubated with 20 µl anti-FLAG M2 
magnetic beads (Sigma) or cMYC-tagged proteins were purified with 
Myc-TRAP MA magnetic agarose beads (Chromotek) at 4°C 
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overnight. The IP reaction was washed three times with the co-IP 
buffer, incubated in 2× sample loading buffer (100 mM Tris/HCl pH 
6.8, 100 mM DTT, 4% SDS, 0.2% bromophenol blue and 20% 
glycerol) for 10 min at 90°C, then subjected to Western blot using 
standard methods. Blots were incubated with primary antibodies and 
were developed using Westernbright ECL (Advasta) according to the 
manufacturer’s instructions. Quantification was performed on scanned 
images of blots using Image Lab software. 
PLA (Proximity-Ligation Assay) 
The in-situ proximity-ligation assay (PLA; mouse/rabbit red starter 
Duolink kit from Sigma-Aldrich) was used as indicated by the 
manufacturer. Images were acquired with Eclipse 80i Nikon 
Fluorescence Microscope, equipped with a VideoConfocal (ViCo) 
system. For each point, at least 500 nuclei were examined and foci 
were scored at 40×. Parallel samples incubated with only one primary 
antibody confirmed that the observed fluorescence was not 
attributable to artefacts. Only nuclei showing more than four bright 
foci were counted as positive. 
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Antibodies 
The primary antibodies used were: anti-MUS81 (1:1000; Santa Cruz 
Biotechnologies), anti-DDK (Flag Origene, WB 1:1000, IF 1:200), 
anti-cMYC (1:1000;Abcam), , anti-CK2 (1:1000; Cell signaling 
technologies), anti-RxxpS/T (1:1000; Cell signaling technologies), 
anti-SLX4 (WB 1:1000, IF 1:200, Novus biologicals), anti-pS10H3 
(1:1000, Santa Cruz Biotechnologies), anti- H3(1:1000, Santa Cruz 
Biotechnologies), anti-EME1 (1:1000, Santa Cruz Biotechnologies), 
anti EME2 (1:500, Invitrogen), anti-Cyclin A (WB: 1:1000, IF: 1:100, 
Santa Cruz Biotechnologies), anti 53BP1 (1:400, Millipore), anti-
BrdU (1:50, Becton Dickinson), anti-pS139H2A.X (1:1000, 
Millipore), anti-ɣ-Tubulin (1:200, Sigma-Aldrich), anti-pS87MUS81 
(WB 1:1000, IF 1:200, Abgent), BLM (sc-7790, Santa Cruz 
Biotechnology, IF 1:50), anti-BRCA2 (1:1000, Bethyl) and anti-
Lamin B1 (1:10000; Abcam). HRP-conjugated matched secondary 
antibodies were from Jackson Immunoresearch and were used at 
1:40000.  
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Chromatin fractionation 
Cells (4 × 106cells/ml) were resuspended in buffer A (10 mM HEPES, 
[pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 
1 mM DTT, 50 mM sodium fluoride, protease inhibitors [Roche]). 
Triton X-100 (0.1%) was added, and the cells were incubated for 5 
min on ice. Nuclei were collected in pellet by low-speed centrifugation 
(4 min, 1,300 ×g, 4°C) and washed once in buffer A. Nuclei were then 
lysed in buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, protease 
inhibitors). Insoluble chromatin was collected by centrifugation (4 
min, 1,700 × g, 4°C), washed once in buffer B + 50mM NaCl, and 
centrifuged again under the same conditions. The final chromatin 
pellet was resuspended in 2X Laemmli buffer and sonicated for 15 s 
in a Tekmar CV26 sonicator using a microtip at 25% amplitude. 
Immunofluorescence 
Immunofluorescence microscopy was performed on cells grown on 
35-mm cover- slips and harvested at the indicated times after 
treatments. For IF, after further washing with PBS, cells were fixed 
with 4% PFA/PBS at RT for 10 min and were permeabilized with 
0,5% Triton-X 100. After blocking in 3% BSA for 15 min, staining 
75 
 
was performed with the indicated antibody. Nocodazole-treated cells 
were blocked and fix with PTEMF buffer (29). After blocking, 
coverslips were incubated for 1hat RT with the indicated antibodies. 
For detection of anti- BrdU, after permeabilization with 0,4%Triton-
X 100/PBS, cells were denatured in HCl 2,5N for 45’ at RT. Alexa 
Fluor® 488 conjugated-goat anti mouse, Alexa Fluor® 594 
conjugated-goat anti rabbit and Alexa Fluor® 488 conjugated-goat 
anti donkey secondary antibodies (Life Technologies) were used at 
1:200. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI 
1:4000, Serva). Coverslips were observed at 40× objective with the 
Eclipse 80i Nikon Fluorescence Microscope, equipped with a 
VideoConfocal (ViCo) system. Images were processed by using 
Photoshop (Adobe) program to adjust contrast and brightness. For 
each time point at least 200 nuclei were examined. Parallel samples 
incubated with either the appropriate normal serum or only with the 
secondary antibody confirmed that the observed fluorescence pattern 
was not attributable to artefacts. Experiments for labeling cellular 
DNA with EdU (5-ethynyl-2’-deoxyuridine). EdU was added to the 
culture media (10μM), for 30 min. Detection of EdU was performed 
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used Click-iT EdU imaging Kits (Invitrogen).  For UFBs-
immunofluorescence analyses, cells grown on coverslips were fixed 
with PTEMF buffer (20 mM PIPES pH 6.8, 0.2% Triton X-100, 1 mM 
MgCl2, 10 mM EGTA and 4% PFA) for 20 min. Cells were then 
processed as described above.   
Cell cycle analysis by flow cytometry 
Cells were processed for flow cytometry as follows: for each point, 
106 cells were collected, and after two washes in PBS, fixed in 70% 
cold ethanol. Then, cells were washed in PBS/BSA 1% and then 
resuspended in 0.5μg/ml propidium iodide and 0.1mg/ml RNase 
before analysis. Data were analysed with CellQuest and ModFit LT 
4.1. software. Bivariate flow cytometry was performed for anti-BrdU 
and anti-γ-H2AX staining as indicated in the Anti-BrdU data-sheet 
(Becton Dickinson).  
Growth Curve 
The cells were seeded at 1.8 x 104 cells per plate. After trypsinization, 
cells were counted through electronic counting cells (BioRad) for the 
following 6 days. The growth curve of the cell cultures was expressed 
as number of cells as a function of time. 
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Chromosomal aberrations 
MRC5 SV40 cells were treated with Aph (low doses) at 37°C for 18h. 
Cell cultures were incubated with colcemid (0.2 µg/ml) at 37 °C for 
3h until harvesting. Cell suspension was dropped onto cold, wet slides 
to make chromosome preparations. The slides were air dried 
overnight, then for each condition of treatment, the number of breaks 
and gaps was observed on Giemsa-stained metaphases. For each time 
point, at least 50 chromosomes were examined by two independent 
investigators and chromosomal damage was scored at 
100×magnification with an Olympus fluorescence microscope. For 
each time point at least 100 chromosomes were examined by two 
independent investigators and chromosomal damage scored at 100×. 
Clonogenic assays 
Cells were plated at densities between 800 and 1000 cells per well in 
6-well plates. Colonies were fixed in methanol-acetic aicid 3:1 and 
stained with 5mg/ml-1 GIEMSA (Sigma). Cell survival was expressed 
relative to control cells.  
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Phosphorylation site prediction 
For the prediction of MUS81 phosphorylation sites, the MUS81 
protein sequence was scanned using the GPS 2.0 sofware 
(http://gps.biocuckoo.org/download.php) with a medium threshold 
that consist in a < 6% of false identification rate (Xue et al., 2008). 
Production and purification of GST-fused fragments 
The different fragments of MUS81 were amplified by PCR from the 
pCMV-Tag2B-MUS81 plasmid (Stratagene) containing the full-
length MUS81 ORF. PCR-amplified DNA was cloned into the GST-
pGEX-2TK plasmid (Stratagene). GST-MUS81 fragments were 
expressed into E. coli BL21PlysS at 30°C for 4h. Bacterial pellets 
were lysed in BER reagent (Pierce) supplemented with DNase and 
Lysozyme, as indicated by the manufacturer, and purified by 
incubation with GSH-magnetic beads (Promega) after extensive 
washings, as reported previously (Pichierri et al, 2012). Quantification 
of the magnetic-beads-bound fragments was performed after SDS-
PAGE and Coomassie staining against serial dilutions of purified 
BSA. Magnetic beads-bound GST-MUS81 fragments were then used 
as substrates for in vitro kinase assays. 
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Phospho-peptide antibody and Dot-blot 
Phosphopeptide antibodies were raised in rabbit against the KLH- 
conjugated phosphopeptide (NH2)- 
DGLCRMLDERLQRHRTpSGGD-(COOH) for S87 phospho-
specific antibody (Abgent). Antibodies were affinity purified using 
phosphopeptide columns and contaminating non-phosphospecific 
antibody was affinity depleted by passing through a column cross-
linked with non-phosphopeptide (NH2)- 
DGLCRMLDERLQRHRTSGGD-(COOH). The eluted phospho-
specific MUS81 antibodies were then enriched by dialysis against 
TBS containing 50% glycerol and tested by the vendor. The delivered 
antibody showed a 100-fold higher affinity for the phosphorylated 
peptide as evaluated by the vendor using an ELISA plate assay. To 
evaluate the ability of the pS87-WRN antibody to discriminate 
between unphosphorylated and phosphorylated pepetide containing 
S87 in our hands, peptides were subjected to kinase assays and spotted 
onto a nitrocellulose strip. After incubation for 1 h at room 
temperature to ensure that the blots are dry, the strip was blocked with 
5% dry milk in TBS (50 mM Tris, 0.5 M NaCl, 0.05% Tween-20, pH 
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7.4) for 1 h at room temperature and incubate with 100ng/ml of the 
rabbit anti-pS87-MUS81 primary antibody for 1hr at RT in 5% 
NFDM-TBS. After extensive washing, blot was detected with 
enhanced chemiluminescent reagents and images acquired through the 
ChemiDoc system (Bio-Rad). 
Endonuclease activity assay 
The functional activity of MUS81 was determined by performing an 
incision assay on a synthetic substrate mimicking a nicked Holliday 
Junction (nHJ). The DNA substrate was built by annealing five 
oligomers purchased from Thermo Fisher Scientific Inc., Waltham, 
MA. One of them was 5’ end labelled with 6-carboxyfluorescein (6-
FAM). Oligomer sequences and the substrate structure are in Figure 
S8. FLAG-tagged MUS81 mutants were affinity purified from cleared 
lysates by using anti-FLAG M2 magnetic beads (Sigma-Aldrich) 
according to the CoIP protocol indicate din the standard Methods. 
Beads were extensively washed and the immunopurified FLAG-
MUS81 complexes were mixed with 50 nM of DNA substrate in 10 
µl of reaction buffer (25mM Hepes, 100mM NaCl, 3mM Mg(OAc)2, 
1mM DTT, 100µg/ml BSA). After 90 min of incubation at 30°C, DNA 
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products were deproteinized for 30 min at 37°C by addition of 10µl 
stop buffer (2 mg/ml proteinase K and 0,1% SDS). Reaction products 
were separated by a 15% native PAGE, at 400V for 2h at 4°C. 
Fluorescent bands were visualized by Typhoon 9200 Gel Imager (GE 
Healthcare, Uppsala, Sweden) and quantified using the public domain 
ImageJ software (available on line at: http://rsb.info.nih.gov/ij/). Data 
analysis was performed by Kaleidagraph (Synergy software). 
Phosphopeptide enrichment 
Purification of phosphopeptides was then performed according to 
Thingholm et al. (Thingholm et al, 2006). Briefly, tryptic peptides 
were diluted 5-fold in dihydroxybenzoic acid (DHB) buffer [350 
mg/mL DHB, 80% (v/v) ACN, 2% (v/v) TFA] and applied to TiO2 
beads (200 μg) pre-equilibrated in 50% ACN. The sample was then 
washed once in DHB buffer, before being washed two times with wash 
buffer [80% ACN (v/v), 2% TFA (v/v)] to remove the DHB. The 
sample was finally eluted with 25 μL of 2.5% ammonium hydroxide 
solution (pH≥10.5) and immediately neutralized with 2.5 μL of formic 
acid. All buffers used ultrapure water and were made fresh on the day 
of experimentation. 
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LC–ESI–CID/ETD–MS/MS 
The TiO2-enriched samples were analyzed using a split-free nano-
flow liquid chromatography system (EASY-nLC II, Proxeon, Odense, 
Denmark) coupled to a 3D-ion trap (model AmaZon ETD, Bruker 
Daltonik, Germany) equipped with an online ESI nano-sprayer (the 
spray capillary was a fused silica capillary, 0.090mm o.d., 0.020mm 
i.d.). A sample volume of 15 μL was loaded by the autosampler onto 
a homemade 2 cm fused silica precolumn (100 μm I.D.; 375 μm 
O.D.;Reprosil C18-AQ, 5 μm, Dr. Maisch GmbH, Ammerbuch- 
Entringen, Germany). Sequential elution of peptides was 
accomplished using a flow rate of 300 nL/min and a linear gradient 
from Solution A (2% acetonitrile; 0.1% formic acid) to 50% of 
Solution B (98% acetonitrile; 0.1% formic acid) in 40 min over the 
precolumn in-line with a homemade 15 cm resolving column (75 μm 
I.D.; 375 μm O.D.; Reprosil C18-AQ, 3 μm, Dr. Maisch GmbH, 
Ammerbuch-Entringen, Germany). To identify phosphorylation sites, 
two types of peptide fragmentation were carried out in parallel in the 
mass spectrometer: (i) Collision Induced Dissociation (CID); (ii) 
Electron Transfer Dissociation (ETD). When CID was used a MS2 
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was automatically performed on the three most intense MS ions, and 
MS3 was triggered if one of the top three MS2 peaks corresponded 
with neutral loss of 98.0, 49.0, 32.7 m/z. For ETD experiments the 
reaction time was set to 100 ms using a reactant ICC of 500000 
allowing a maximum accumulation time for the reactant ion of 10 ms. 
Acquired MS/MS spectra were processed in DataAnalysis 4.0, and 
submitted to Mascot search program (in-house version 2.5, Matrix 
Science, London, UK). The following parameters were adopted for 
database searches: SwissProt database (release date 12/06/2015); 
taxonomy=homo sapiens; peptide mass tolerance of ±0.3 Da; 
fragment mass tolerance of ±0.3 for CID ions and of±1.3 Da for ETD 
ions; enzyme specificity trypsin with 1 missed cleavages considered; 
fixed modifications: carbamidomethyl (C); variable modifications: 
oxidation (M), phosphorylation (STY). Phosphopeptide 
identifications were accepted if the Mascot score was over the 95% 
confidence limit based on the “identity” score of each peptide. A delta 
ion score was calculated of all phosphopeptides containing more than 
one serine, threonine or tyrosine residues by taking the difference 
between the two top-ranking Mascot ion scores. Phosphorylation site 
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assignments with a delta score > 5 were automatically accepted. All 
fragmentation spectra with delta score ≤ 5 were manually inspected as 
to whether the phosphorylation sites were unambiguously determined 
or not. 
DNA fibre assay  
The efficiency of replication recovery was measured using the DNA 
fibre assay. First, DNA replication sites were labelled with 25 mM IdU 
(15 min), then cells were washed twice with PBS and incubated for 
other 15 min in fresh medium with 50 mM CldU. For 
immunodetection of labelled tracts, the following primary antibodies 
were used: rat anti-CldU/BrdU (Abcam) and mouse anti-IdU/BrdU 
(Becton Dickinson). Images were acquired randomly from fields with 
untangled fibres using the Eclipse 80i Nikon Fluorescence 
Microscope, equipped with a VideoConfocal (ViCo) system. The 
lengths of labelled tracts were measured using the Image-Pro-Plus 6.0 
software. A minimum of 100 individual fibres were analysed for each 
experiment and each experiment was repeated three times. In dot plots, 
the mean of at least three independent experiments are presented. The 
value of the IdU tract length is reported in micrometers. 
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Statistical analysis 
All the data are presented as means of at least three independent 
experiments. Statistical comparisons were made by Student's t test or 
by Anova, as indicated. P < 0.5 was considered significant. 
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AIM OF THE WORK 
Replication stress represents a major source of genome instability 
stemming from slow rates of DNA synthesis, aberrant origin firing and 
frequent stalling of replication forks. Treatment with agents that 
interfere with DNA replication (for example, hydroxyurea, 
aphidicolin), as well as oncogene overexpression are known to trigger 
replication stress. Hence, cells are equipped with pathways that 
recognize and process branched DNA structures. Structure-specific 
endonucleases (SSEs) have key roles in DNA replication, 
recombination and repair, and emerging roles in transcription. These 
enzymes have specificity for DNA secondary structure rather than for 
sequence, and therefore their activity must be precisely controlled to 
ensure genome stability. Recombinogenic and non-recombinogenic 
pathways ensure replication recovery failure to protect or process 
stalled forks appropriately for replication restart results in 
accumulations of DNA double-strand breaks (DSBs) and 
chromosomal rearrangements. Among these, HR was believed to play 
an important role in the recovery of stalled or broken replication forks 
(RFs) during DNA replication and contributes to tolerance of DNA 
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damage. In addition, HR provides critical support for the correct 
segregation of homologous chromosomes during the first meiotic 
division. In all these events, a major step is the formation of Holliday 
junctions (HJs), four-way branched DNA intermediates, which must 
be resolved to separate repaired chromosome. One of these pathways 
utilizes the structure-selective endonuclease MUS81, which was 
thought to facilitate the resolution of replication and recombination 
intermediates. Many of our knowledge about the MUS81 nuclease has 
been obtained during the last years, but new studies indicate a growing 
importance about how cells control MUS81 function during cell cycle 
and its correlation with the subunits EME1/2. Several in vivo and in 
vitro studies have indicated that the primary role for MUS81 is to 
resolve HJs. 
The regulatory circuit of MUS81 described in this elaborate is quite 
different from previous work in budding or fission yeast, where the 
control of the Mus81-Mms4(Eme1) endonuclease activity takes place 
mainly through cell cycle regulated phosphorylation of Mms4(Eme1). 
In fact, not only little is known about the regulation of the human 
MUS81 complex but we also have no evidence of a specific regulation 
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on MUS81 and how deregulated activation affects chromosome 
integrity. Analysis by MS/MS identified several phosphorylated 
residues, including S87, which reveals itself very intriguing also 
because lie within a putative CK2 consensus sequence. During my 
doctoral work, I investigate what is the phospho-regulatory 
mechanism controlling the MUS81 function in human cells. To 
functionally analyse the role of MUS81 S87 phosphorylation, we 
generated MUS81 knock-down cells stably expressing RNAi-resistant 
wild-type, unphosphorylable (S87A) or phosphomimetic (S87D) 
MUS81 forms. Functional analysis on cells expressing S87A or S87D 
forms of MUS81 revealed that phosphorylation at S87 is cell cycle (at 
G2/M) and mild replication stress (low doses of Aphidicolin) 
dependent and is sufficient to modulate the biological function of the 
MUS81 complex. Using phosphomutants, we also demonstrate that 
abrogation of phosphorylation at S87 of MUS81 is sufficient to 
prevent formation of DSBs after replication stress, phenocopying 
depletion of MUS81. Indeed, and in line with a role in mitosis, 
phosphorylation at Serine 87 is suppressed in S-phase and mainly 
detected in the MUS81 molecules associated with EME1. 
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Activation of MUS81 in mitotic cells has been linked to association of 
the MUS81/EME1 complex with the SLX4 scaffolding protein. SLX4 
is indeed necessary to support MUS81 function at demised replication 
forks; we also investigate on modulation of the MUS81/SLX4 
interaction by phosphorylation at S87.    
Our findings involve CK2-dependent phosphorylation of MUS81 as 
crucial in the activation of endonucleolytic cleavage under replication 
stress. CK2 has been recently shown to phosphorylate RAD51 (Yata 
et al., 2012) thus its activity could be crucial for replication recovery 
under stressed conditions. Interestingly, CK2 has been found 
overexpressed in many human cancers (Ruzzene & Pinna, 2010). 
Thus, it is tempting to speculate that the hyperactivation of CK2 in 
such tumours could be results in a higher phospho-activation of 
MUS81 resulting in more genome instability and contributing to 
enhance aggressiveness. 
In the last part of my doctoral studies I started to investigate if our 
S87-MUS81 phosphorylation mutant could be a useful tool to define 
which function of MUS81, the S-phase-related one or that performed  
in M-phase, was essential under pathological conditions. As a  
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prototype of pathological condition, we used cells lacking BRCA2 that 
needs MUS81 to recover from replication stress. Using cell biology 
approaches to evaluate survival, DNA damage and resolution of 
mitotic interlinked intermediates, we show that the S87 MUS81 
phosphorylation is involved to ensure viability of BRCA2-deficient 
cells mostly because it is the M-phase function of MUS81 to be 
essential.  
Moreover, we show that the resistance of phosphomimic mutant of 
MUS81 to Olaparib treatment in cells lacking BRCA2 could be a be 
used as a potential target for the development of drugs that could 
selectively eliminate BRCA2-compromised cells and tumours. 
Altogether, our data described a novel regulatory mechanism required 
to control MUS81 complex function in M-phase in human cells and 
involved in the viability of BRCA2-deficient cells. As CK2 inhibitors 
are under evaluation as anti-cancer drugs, our data may be useful to 
evaluate their use in tumors with signs of BRCAness.  
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RESULTS 
PART I 
1. MUS81 is phosphorylated at Serine 87 by the protein kinase 
CK2 both in vitro and in vivo 
The human MUS81 contains an N-terminal unstructured region and a 
HhH domain that are essential to associate with SLX4, a crucial step 
for the biological function of the complex in mitosis(Dehé & Gaillard, 
2017). Hence, seeking for regulatory events modulating theMUS81 
complex, we scanned the N terminal sequence of MUS81 comprising 
amino acids 1–200, which includes the SLX4 binding region, for the 
presence of putative phosphorylation sites of mitotic kinases. As 
shown in Table 1, bioinformatics analysis retrieved several CDKs, 
PLK1 and CK2 putative phosphorylation sites that score over the 
specificity threshold of the software. As CK2 was not previously 
associated to MUS81 regulation and its pharmacological inhibition 
interfered with the formation of MUS81-dependent DSBs in 
checkpoint-deficient cells (Forment et al., 2011; Murfuni et al., 2013) 
(Fig. 16), we decided to focus on this kinase. Hence, to test whether  
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CK2 could phosphorylate MUS81 in vitro, we performed a radioactive 
kinase assay. As substrates, we used two different fragments 
comprising residues 1–206 or 76–206 of MUS81, fused to GST and 
purified from bacteria (Fig. 15A). Our kinase assays showed that CK2 
efficiently phosphorylates the N-terminal MUS81 fragments (Fig. 
15B). To confirm phosphorylation and identify phosphoresidues, we 
incubated the fragment 76–206 of MUS81 with recombinant CK2 and 
analysed the product of the reaction byMS/MSafter affinity-
purification of the phosphorylated peptides. From the CK2-modified 
fragment, we identified three different peptides containing 
phosphorylated residues (Fig. 15C). Among the three identified 
residues, S87 was the most promising because it is very close to the 
SLX4-interacting region of MUS81 (Nair et al., 2014). Hence, to 
functionally characterize this phosphorylation event, we generated a 
phosphospecific antibody that recognizes the MUS81 protein 
modified at S87. Dot blot assay confirmed that the antipS87MUS81 
antibody efficiently recognizes the modified peptide or the peptide  
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incubated with recombinant CK2, while it showed no antibody 
reaction with the peptide incubated with recombinant PLK1 
(Fig.17A). 
Phosphorylation of MUS81 was also confirmed using a commercial 
phosphomotif antibody that recognizes a sequence (RXXpS/T) very 
similar to that surrounding S87 (RHRTpS) (Fig. 17B). Finally, co-
immunoprecipitation experiments revealed interaction between the 
catalytic subunit of the CK2 holoenzyme, CK2α, and MUS81, 
supporting the possible physiological relevance of S87 modification 
(Fig. 17C). Next, we performed in vivo experiments to test the ability 
of the anti-pS87MUS81 antibody to detect MUS81 phosphorylation. 
To this aim, HEK293T cells stably expressing a shRNA sequence 
against MUS81 (HEK293TshMUS81) were transiently transfected 
with empty vector or with plasmids expressing the wild-type, the 
unphosphorylable (S87A) or the phosphomimetic (S87D) FLAG-
tagged RNAi-resistant form of MUS81 protein. After anti-FLAG 
immunoprecipitation, the presence of MUS81 phosphorylation was 
analysed by western blotting. As shown in Fig. 18A S87 
phosphorylation was detected only in the wild-type protein,  
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confirming S87 modification in vivo and the specificity of the 
antibody. This result was further corroborated by immunofluorescence 
in MRC5SV40 cells stably expressing the shMUS81 construct 
(shMUS81), and shMUS81 cells complemented with the FLAG-
tagged-RNAi-resistant form of wild-type MUS81 or each of the two 
phosphorylation mutants and enriched in mitosis using nocodazole 
(Fig. 18B). Our analysis revealed the presence of nuclear staining in 
MUS81WT cells, which was not detectable in shMUS81 cells or in 
cells expressing the MUS81 mutant forms (MUS81S87A and 
MUS81S87D; Fig. 18B). Similarly, evaluation of MUS81 S87 
phosphorylation by Western blotting in transiently expressing cells 
enriched in M-phase by nocodazole treatment confirmed that the anti-
pS87 antibody efficiently recognised the MUS81 wild-type but not the 
phosphorylation mutant forms (Fig. 18C). Interestingly, 
pharmacological inhibition of CK2 substantially reduced S87 
phosphorylation as evaluated by IP/WB or immunofluorescence 
analysis (Fig. 19A and B), proving that S87 residue of MUS81 is an 
in vivo substrate of the protein kinase CK2. 
Altogether, our findings show thatMUS81 is phosphorylated by CK2  
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on S87 both in vitro and in vivo, and that S87 phosphorylation is 
already detectable during unperturbed cell growth. 
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Figure 15 CK2 phosphorylates MUS81 in vitro. (A) Schematic representation of the 
N-terminal MUS81 fragments. (B) GST-fused N-terminal MUS81fragments purified 
from bacteria were incubated with recombinant CK2 and subjected to in vitro 
radioactive kinase assay. Caseins were used as positive control. Red boxes indicate 
position of the fragments. Parenthesis indicates N1-MUS81 degradation products. 
Asterisk denotes residual co-purifying autophosphorylated CK2. (C) MS/MS analyses 
of in vitro phosphorylated N2-MUS81. Inset summarizes the identified 
phosphopeptides and residues. 
 
 
 
 
 
Figure 16 CK2 inhibition suppresses MUS81-dependent DSBs. Cells were treated as 
indicated for 6 h, in the presence or not of CK2 inhibitor (CK2i), before being 
analyzed for the presence of DSBs by neutral Comet assays. The CHK1 inhibitor 
UCN01 was used at 400 nM. Data are presented as mean tail moment ± SE from three 
independent experiments. Error bars represent standard errors. **** = p>0.001; 
Student’s t-test. 
97 
 
 
 
 
 
 
Figure 17 CK2 phosphorylates full-length MUS81 on S87 and they form a complex. 
(A) Fifty nanograms of peptide or phosphopeptide used as antigen to generate the 
polyclonal rabbit antipS87MUS81 was incubated with the indicated recombinant 
kinase and ATP.  Reaction products were spotted onto a nitrocellulose strip and 
subjected to WB using the pS87MUS81 antibody. (B) Immunopurified MUS81 Full-
Length (FL) protein was incubated with recombinant CK2 kinase and ATP. 
Phosphorylation was analyzed after WB with anti-pS87MUS81 or anti-RXXpST 
antibodies. (C) MUS81 was immunoprecipitated from MRC5 shMUS81 
complemented or not with RNAi resistant FLAG-MUS81wt protein after 
synchronization with Nocodazole for 16h. The presence of CK2 in the MUS81 IP was 
revealed by WB by using anti-CK2α subunit antibody. 
A 
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Figure 18 The anti-pS87MUS81 antibody can 
detect S87-phosphorylated MUS81 in cells. (A) 
HEK293T shMUS81 were transiently transfected 
with empty vector or with plasmids expressing the 
wild-type, the unphosphorylable S87A or the 
phosphomimetic S87D FLAG-tagged RNAi 
resistant MUS81 proteins. After anti-FLAG 
immunoprecipitation, the anti-pS87MUS81 
antibody signal was revealed by WB only in the 
wild type protein. MUS81 expression and Lamin B1 housekeeping protein were 
shown in the input as control. EV=Empty Vector. (B) Immunofluorescence 
experiments performed in MRC5SV40 shMUS81 cells stably complemented with the  
A B 
C 
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FLAG-tagged form of MUS81 wild-type or the S87A/S87D phosphorylation mutants. 
MUS81 expression and Lamin B1 as loading control were revealed by WB. The 
representative images showed pS87MUS81 antibody signal (red staining) in NOC 
synchronized cells. Nuclei were depicted with DAPI staining (blue). (C) Anti-FLAG 
immunoprecipitation performed as described in (A) with HEK293T cells treated with 
NOC. 
 
Figure 19 CK2 inhibition abrogated S87 MUS81 phosphorylation in vivo. (A) After 
transient transfection, FLAG-MUS81wt was immunoprecipitated from HEK293T 
shMUS81 cells treated as indicated. Cells were accumulated in S-phase by using a 
double-thymidine block (Thy+2h rec) or in mitosis upon Noc treatment. The CK2 
inhibitor was used at 25μM added for the last 6 hours. The anti-pS87MUS81 signal 
was expressed as normalized percentage of the total immunoprecipitated MUS81.  
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(B) Representative images of immunofluorescence experiments performed to detect 
MUS81 S87-phosphorylation upon CK2 inhibition in MRC5 shMUS81 cells stably   
complemented with MUS81wt. Cells were synchronized by NOC treatment and the 
last 6 hours we added DMSO or 25μM CK2 inhibitor. Representative images were 
shown. The mean percentage of pS87MUS81 positive cells is indicated in the images 
± SE. 
2. CK2-mediated phosphorylation ofMUS81 at Serine 87 is an 
early mitotic event stimulated by mild replication stress and 
restrained in the MUS81/EME2 complex 
It is still poorly defined whether each of the two MUS81/EMEs 
complexes shows any cell-cycle specificity (Duda et al., 2016; Matos 
& West, 2014; Pepe & West, 2014; Pfander & Matos, 2017a). Hence, 
we analysed if modification by CK2 was cell cycle-dependent. To this 
aim, HEK293TshMUS81 cells, transiently expressing the wild-type 
form of MUS81, were synchronized and S87 phosphorylation was 
determined. Phosphorylation was evaluated by IP/WB using the anti-
pS87MUS81 antibody from cells enriched in S-phase after release 
from a double-thymidine block or in mitosis using Nocodazole (Noc; 
Fig. 20A). Although MUS81 was found phosphorylated at S87 already 
in asynchronous cells, the level of phosphorylation was substantially 
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reduced in S-phase enriched cells, but it was increased in mitotic cells 
(Fig. 20B). To evaluate phosphorylation in a more physiological 
context, we performed anti-pS87MUS81 immunofluorescence in 
asynchronous cultures exposed to a short EdU pulse to label S-phase 
cells or, as a control, in Noc-arrested cultures. Dual EdU/pS87MUS81  
immunostaining revealed that CK2-dependent phosphorylation is 
absent in S-phase cells, while it is easily detected after Noc treatment 
(Fig. 20C). Although the most relevant function of theMUS81 
complex is the resolution of recombination intermediates in late 
G2/M, it may also process perturbed or collapsed replication forks 
(Sarbajna & West, 2014). Thus, we analysed if phosphorylation of S87 
might be a common readout of the MUS81 complex activation. To this 
end, we treated HEK293TshMUS81 cells expressing the wild-type 
FLAG-MUS81 protein with two doses of aphidicolin (Aph), which 
partially arrest replication or perturb common fragile sites (CFS), or 
with hydroxyurea (HU). Phosphorylation was then assessed in anti-
FLAG IP by WB using the anti-pS87MUS81 antibody. All these 
treatments have been reported to stimulate the function of both the 
MUS81 complexes, however, prolonged treatment with HU leads to a  
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complete arrest of S-phase progression and formation of MUS81-
dependent DSBs (Fugger et al., 2015; Hanada et al., 2007; Naim et al., 
2013; Ying et al., 2013c). Consistently, Aph treatment accumulated 
cells in S-phase but did not completely arrest cell cycle progression, 
while 24 h of HU blocked cells in G1/S phase (Fig. 21). As expected,  
phosphorylation of S87 was increased in Noc-treated cells, but it was 
also stimulated by Aph treatments (Fig. 20D). In contrast, and despite 
the reported formation of DSBs by MUS81, phosphorylation of 
S87was barely detectable in cells treated with HU (Fig. 20D). To 
confirm that treatment with Aph stimulated phosphorylation of 
MUS81 at S87, we performed anti-pS87MUS81/EdU 
immunofluorescence in shMUS81 cells complemented with the wild-
type form of MUS81 (Fig. 20E). Treatment with a low-dose Aph 
increased the number of nuclei positive to anti-pS87MUS81 
immunostaining and the large majority of cells staining positive for 
pS87 were EdU-negative. This indicates that a mild replication stress 
induces a CK2-dependent phosphorylation of MUS81 most likely in 
G2/M phase. Although it is widely accepted that the MUS81 complex 
carries out its primary function in late G2 and mitosis, it is still unclear  
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if it is active throughout all this period. Our data suggest that 
phosphorylation at S87 can be used as diagnostic sign ofMUS81 
complex function. Hence, we performed immunofluorescence to 
followMUS81 modification over time after release from a G2-arrest 
induced by CDK1 inhibition (Minocherhomji et al., 2015a), as 
outlined in the experimental scheme (Fig. 20F). Cells released in late 
G2/M were subjected to anti-pS87MUS81 immunofluorescence at 
different time-points. Cells blocked in late-G2 showed high levels of 
pS87MUS81 immunostaining, which increased during the early time-
point after release in mitosis (Fig. 20G). Anti-pS87MUS81 nuclear 
staining declined thereafter in concomitance with appearance of 
metaphase cells, as evaluated by DAPI staining (Fig. 20G). 
Interestingly, pS87MUS81 nuclear immunostaining was always 
confined to cells with morphological features of late G2/prophase, 
even at later post-release time-points, when population was enriched 
of metaphase and anaphase cells (30 and 45 min; Fig. 20G). Of note, 
in several late mitotic cells, pS87MUS81 immunostaining was 
apparently accumulated at centrosomal regions (see 45 min) as 
indicated by anti-tubulin co-staining (Fig. 20H). In human cells,  
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MUS81 exists as an heteroduplex in association with EME1 or EME2 
(Ciccia et al., 2007). Although there are conflicting results about the 
cell cycle-dependent association with EME2(Duda, et al., 2016; Pepe 
& West, 2014b), EME1 is found throughout the cell cycle, even if its 
function predominates in G2/M (Pepe & West, 2014b).  
Since phosphorylation of S87 is stimulated in early mitosis and is 
absent in S-phase synchronized cells, we investigated if it was 
confined to the MUS81/EME1 complex. To this end, we transiently 
expressed FLAG-MUS81 and Myc-EME2 or Myc-EME1 in 
HEK293T cells, and immunopurified the fraction of MUS81 
associated with EME2 or EME1 by anti-Myc immunoprecipitation. 
We analysed S87 MUS81 phosphorylation in asynchronous cells or in 
cells accumulated in M-phase with Noc. As shown in Fig. 22, S87 
MUS81 phosphorylation was detectable in both the MUS81 
complexes but with different levels. In theMUS81/EME1 complex, 
S87MUS81 phosphorylation was enhanced by nocodazole treatment 
by about 3-fold over the basal level while, in the MUS81/EME2 
complex phosphorylation was similar in asynchronous cells but did 
not change after nocodazole treatment. Collectively, these results  
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demonstrate that CK2 phosphorylates MUS81 at S87 in early mitosis, 
and that this phosphorylation is stimulated in the presence of mild 
replication stress. Furthermore, they suggest that phosphorylation of 
S87 is prevented in S-phase and mainly concerns the MUS81/EME1 
complex. 
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Figure 20 Phosphorylation of MUS81 on S87 is cell cycle-dependent and confined in 
early mitosis. (A) Flow cytometry analysis of HEK293T shMUS81 cells transiently 
expressing the wild-type form of FLAG-MUS81 after synchronization in S-phase 
(Thy+2h rec) or in mitosis (Noc). (B) After transient transfection, FLAG-MUS81wt 
was immunoprecipitated from asynchronous (asynchr), S-phase or M-phase 
synchronizedHEK293T shMUS81. Phosphorylation was analyzed by WB by using 
the anti-pS87MUS81 antibody, and the anti-pS87MUS81 signal was expressed as 
normalized percentage of the total immunoprecipitated MUS81. EV = Empty Vector 
(C) Anti-pS87MUS81 immunofluorescence staining (red) was performed 
inMRC5SV40 shMUS81 and FLAG-MUS81wt stably complemented cells 
previously exposed to short EdU pulse to mark S-phase cells (green). Nuclei were 
depicted by DAPI staining (blue). (D) After transient transfection, FLAG-MUS81wt 
was immunoprecipitated from asynchronous HEK293T shMUS81 cells treated as 
indicated. anti-pS87MUS81 signal was expressed as normalized percentage of the 
total immunoprecipitated MUS81. EV = Empty Vector. (E) Immunofluorescence 
experiments were performed to detect S87MUS81-phosphorylation upon mild 
replication stress induced by low dose ofAphidicolin.MRC5 shMUS81 cells  
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complemented with MUS81wt were exposed to short EdU pulse and then stained with 
anti-pS87 antibody (red) and DAPI (blue). Representative images were shown. (F) 
Experimental scheme used to study S87 MUS81 phosphorylation over time, from G2-
phase arrested cells to late mitosis. MRC5 shMUS81 cells complemented with 
MUS81wt were arrested in G2-phase by treatment with CDKi (RO-3306). Cells were 
immunostained for anti-pS87MUS81 at indicated post-release time points. (G) 
Representative images of anti-pS87MUS81 immunostaining (red). The mean 
percentage of pS87MUS81 positive cells is indicated in the images ± SE. At least 200 
anaphase, 100 metaphase and 50 prophase cells were analysed in three replicates. 
Arrowheads indicate the positive cells enlarged in the insets. (H) Representative 
images of anti-pS87 MUS81antibody (red) co-localization with α-Tubulin antibody 
(green) in metaphase cells. Nuclei were depicted with DAPI. 
 Figure 21 Cell cycle analysis of the population of HEK293T shMUS81 cells 
transfected with FLAG-MUS81. Flow cytometry profile of cells treated as indicated. 
The percentages of cells in each different phase of the cell cycle are shown in the 
panel. 
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Figure 22 MUS81 phosphorylated at 
S87 privileges interaction with 
EME1. HEK293T shMUS81 cells 
were transfected with cMYC plasmid 
alone (control) or together with 
FLAGMUS81wt and cMYC-EME1 
or cMYC-EME2. After treatment 
with Noc for 16h, cMYC-EME1 and 
EME2 were immunoprecipitated 
using anti-cMYC magnetic beads. 
The presence of MUS81 and its phosphorylation status at S87 were analysed by WB. 
The fraction of pS87 MUS81 associated to EME1 or EME2    was normalized on the 
total immunoprecipitated MUS81. 
3. Phosphorylation of MUS81 at Serine 87 by CK2 regulates 
binding to SLX4 
Association of the MUS81 complex with SLX4 is essential for some 
of its function (Dehé & Gaillard, 2017), and given that the SLX4-
binding region is close to S87, we asked whether phosphorylation 
could influence this interaction. To this aim, we performed co-
immunoprecipitation experiments in shMUS81 cells complemented  
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with the wild-type form of wild-type MUS81 or each of the two-
phosphorylation mutants. Of note, in our cell model, the level of SLX4 
apparently decreased in Noc-treated cells (Fig. 23A, input). This 
unexpected decrease seems cell-line specific as it was not observed in 
HEK293T cells (Fig. 19) and may be correlated with proteosomal 
degradation as it can be reduced by MG132 (data not shown). In 
asynchronous wild-type or MUS81S87A cells, little SLX4 was found 
in a complex with MUS81 (Fig. 23A, IP). However, a 2-fold higher 
amount of SLX4 co-immunoprecipitated with MUS81 in 
MUS81S87D cells (Fig. 23A). In Noc-treated cells, association of 
MUS81 with SLX4 was more affected by loss of S87 phosphorylation. 
Indeed, the unphosphorylableMUS81mutant (MUS81S87A) co-
immunoprecipitated less SLX4 than the wild-type or the 
phosphomimic form (MUS81S87D; Fig. 23A). Interestingly, while 
the amount of SLX4 associated with MUS81 was increased by Noc 
treatment in wild-type cells, no modulation was detected in the 
MUS81S87A or in the MUS81S87D mutant (Fig. 23A). In contrast, 
MUS81 immunoprecipitated similar amounts of EME1 independently 
on the phosphorylation status of S87 (Fig. 23A). To further confirm  
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that phosphorylation of S87 affected the interaction of MUS81 with 
SLX4, we analysed protein-protein interaction at the single cell level 
by the proximity-ligation assay (PLA). Interestingly, and consistently 
with biochemical assays, association of MUS81 with SLX4 was 
enhanced in MUS81S87D cells, while it was only barely detectable in 
wild-type cells or in cells expressing the unphosphorylable protein, as 
evaluated by the number of PLA-positive cells (Fig. 23B and C). Of 
note, association of MUS81 with SLX4 is strongly enhanced in the 
presence of the phosphomimic mutant (MUS81S87D) also in cells 
enriched in S-phase by a thymidine block (Fig. 23B and C), even if 
their association should be actively prevented at this stage to avoid 
targeting of replication intermediates (Duda, et al., 2016). 
To test if enhanced association between MUS81 and SLX4 might 
correlate with an increased association with chromatin, we performed 
cellular fractionation experiments in cells treated with Noc or exposed 
to HU for 24 h, a condition in which we observed little if any S87 
phosphorylation (Fig. 20D).Western blotting analysis of the chromatin  
fraction with an anti-MUS81 antibody showed no substantial 
difference in the two phosphorylation mutants, as compared to the  
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wild-type (Fig. 23D). In a similar way, the fraction of chromatin-
associated SLX4 did not vary among the different MUS81 forms, 
however, the amount of EME1 in chromatin was substantially elevated 
in asynchronous or Noc-arrested cells expressing the phosphomimetic 
mutant (Fig. 23D). In contrast, expression of the unphosphorylable 
MUS81 mutant enhanced the level of chromatin associated EME1 and 
EME2 in cells treated with 24h HU, and also increased the amount of 
EME2 in asynchronous, untreated, cells (Fig. 23D). As our results 
indicate that a mutation mimicking constitutive S87 MUS81 
phosphorylation stimulates association with SLX4 but not chromatin 
recruitment, we decided to analyse if this interaction might be required 
for subsequent phosphorylation of MUS81 by CK2.  
Hence, we analysed S87 phosphorylation by anti-pS87MUS81 IF in 
cells transfected or not with siRNAs against SLX4 and accumulated 
in mitosis with Noc. Depletion of SLX4 did not prevent S87 MUS81 
phosphorylation, which is indistinguishable from wild-type cells (Fig. 
23E). Therefore, our data indicate that phosphorylation of S87 by CK2  
is important to stabilize or stimulate the MUS81-SLX4 interaction.  
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Moreover, they suggest that phosphorylation takes place before 
formation of the MUS81/EME1/SLX4 complex.  
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Figure 23 S87-MUS81 phosphorylation regulates SLX4 binding. (A)MUS81 was 
immunoprecipitated from asynchronous or M-phase synchronized cells expressing 
MUS81wt or its phosphorylation mutants. The fraction of SLX4 associated to 
MUS81was normalized on the total immunoprecipitated MUS81. (B) Interaction of 
MUS81 and SLX4 was analysed by PLA in asynchronous, THY and NOC-
synchronized cells. Representative images of PLA fields are shown. MUS81-SLX4 
interaction resulted in red nuclear dots. The mean percentage of PLA-positive cells is 
represented in the graph in (C). (D) Chromatin fraction was prepared from cells 
D 
E 
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expressing MUS81wt or its phosphorylation mutants, and treated as indicated. The 
presence of MUS81 and the indicated proteins in chromatin was assessed by WB. 
Histone H3 was used as loading control protein. Blots are representative of two 
different biological replicates. (E)MUS81 phosphorylation was evaluated by anti-
pS87MUS81 immunofluorescence on cells transfected siCTRL or siSLX4 and 
accumulated in M-phase with Noc. The WB shows actual depletion levels, and images 
are representative of IF. The dispersion graph shows quantification of pS87MUS81 
antibody signal intensities. 
4. Phosphorylation status of MUS81 at S87 controls unscheduled 
targeting of HJ-like intermediates in S-phase 
By regulating interaction with SLX4, phosphorylation of MUS81 S87 
by CK2 may have functional implications. Hence, we used cells 
expressing the S87 MUS81 phosphomutants as a very specific tool to 
analyse the phenotypic consequences of a deregulatedMUS81-EME1 
function, bypassing the need to interfere with cell-cycle kinases. Our 
analysis of cell growth evidenced a substantial delay in the 
proliferation of MUS81S87D cells, while cells expressing the related 
unphosphorylable MUS81 mutant did not show any apparent defect as 
compared to the wild-type (Fig. 24A). Delayed proliferation rate of 
MUS81S87D cells did not correlate with substantial cell cycle defects 
(Fig. 26A).  
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Thus, we analysed if it could derive from accumulation of spontaneous 
DNA damage by doing immunofluorescence against ɣ-H2AX or 
53BP1. MUS81 deficiency or expression of wild-type MUS81 
resulted in low level of ɣ-H2AX-positive cells (<2%) (Fig. 4B). Very 
few nuclei were positive for ɣ-H2AX also in MUS81S87A cells, 
however, their number was increased of about 10-fold in the 
phosphomimic S87D mutant (Fig. 24B). Interestingly, in the S87D 
MUS81 mutant, almost the totality of the ɣ-H2AX-positive cells were 
also Cyclin A-positive (i.e. in S or G2 phase) and the large part (60%) 
were in S-phase (EdU-positive) (Fig. 24C and D). Similarly, the 
portion of 53BP1-foci/Cyclin A double-positive cells in the population 
was increased by expression of the phosphomimic MUS81mutant as 
compared toMUS81S87A or wild type cells (Fig. 24E).  
Flow cytometry analysis of the ɣ-H2AX-positive population 
confirmed that DNA damage arises mostly in S-phase or in G2/M cells 
(Fig. 26B). The higher load of DNA damage in cells expressing the 
phosphomimic S87D MUS81 protein prompted us to analyse if this 
could derive from unscheduled targeting of intermediates during DNA 
replication. We recently demonstrated that ectopic expression of a  
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GFP RuvA fusion protein is sufficient to interfere with formation of 
DSBs by structure-specific endonucleases in human cells during S-
phase (Malacaria, 2017). Hence, we ectopically expressed GFP-RuvA 
in wild-type or in MUS81S87D cells and analysed the presence of 
DNA damage by neutral Comet assay. As shown in Fig. 25A, the 
amount of spontaneous DSBs detected in wild-type cells did not 
decrease upon expression of RuvA. However, expression of RuvA 
significantly decreased the accumulation of DSBs inMUS81S87D 
cells. Similarly, when we analysed the formation of 53BP1 foci after 
ectopic RuvA expression, we observed a substantial reduction of the 
53BP1 focus-forming activity especially in cells expressing the S87D 
MUS81 mutant (Fig. 25B and C). To determine if the incidental 
cleavage of HJ-like intermediates triggered by deregulated 
phosphorylation of MUS81 at S87 might correlate also with increased 
enzymatic activity, we immunopurified FLAG-MUS81 complexes 
from cells transiently over-expressing the wild-type form of MUS81 
or its phosphorylation mutants and assessed the associated 
endonuclease activity after incubation of anti-FLAG 
immunoprecipitates with a model nicked HJ, one of the preferred in 
vitro MUS81 substrates (Fig. 27A). 
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As shown in Fig. 27B, wild type MUS81 apparently cleaved the 
substrate with comparable efficiency between asynchronous and M-
phase enriched cells, while the MUS81-S87D mutant seemed to 
increase its activity in nocodazole-treated cells. In contrast, the 
unphosphorylable MUS81 mutant showed always very little activity. 
Of note, and in agreement with our PLA and the CoIP data (see Fig. 
23), less SLX4 was found associated with the unphosphorylable 
MUS81 mutant (Fig. 27C). Surprisingly, loss of S87 phosphorylation 
MUS81 increased the ability of the protein to immunoprecipitates 
EME2 although the amount of EME1 was unchanged. Collectively our 
findings indicate that deregulated MUS81 phosphorylation at S87 and 
subsequent MUS81-EME1-SLX4 association is sufficient to induce 
DNA damage in S-phase because of incidental cleavage of HJlike 
intermediates, which is not correlated with enhanced enzymatic 
activity.   
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Figure 24 Constitutive phosphorylation of MUS81 at S87 affects cell growth and 
induces DNA damage. (A) Growth curve in shMUS81 cells stably expressing the 
wild-type form of MUS81 and it S87 phosphorylation mutants. Each point represents 
the average number of counts from two independent experiments. (B)Accumulation 
of spontaneous damage in MUS81 phosphorylation mutants. Untreated cells were 
immunostained with ɣ-H2AX antibody, the graph represents the analysis of ɣ-H2AX 
positive cells. Representative images of fluorescence fields are shown (ɣ-H2AX 
M
U
S
8
1
W
T
M
U
S
8
1
S
8
7
A
M
U
S
8
1
S
8
7
D
0
2 0
4 0
6 0
C
y
c
li
n
A
/5
3
B
P
1
 p
o
s
it
iv
e
 c
e
ll
s
 (
%
)
E 
122 
 
antibody: green; nuclear DNA: blue). (C) DNA damage, in S/G2-phase cells, was 
detected by double IF using anti-Cyclin A and ɣ-H2AX antibodies. (D) Analysis of 
the level of DNA damage during replication. Cells in S-phase were labelled by an 
EdU pulse and the graph shows the percentage of EdU (green) and anti-ɣ-H2AX (red) 
positive cells. Nuclear DNA was counterstained by DAPI (blue). (E) Analysis of 
53BP1 foci formation in Cyclin A positive cells. Representative image of fluorescence 
cells stained with anti-53BP1 (green) and anti-Cyclin A (red) antibodies. Nuclear 
DNA was counterstained by DAPI. The graph shows quantification of the 53BP1-
positive Cyclin A-cells. Data are mean values from three independent experiments. 
Statistical analysis was performed by Student’s t-test. Significance is reported 
compared to the wild-type: ***P < 0.01; *P < 0.05. 
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Figure 25 Ectopic GFP-RuvA expression reduces formation of DSBs and 53BP1 foci 
in constitutive-active MUS81 mutant. (A) MRC5 shMUS81 cells, stably expressing 
WT or S87D phosphomimetic MUS81 were transfected or not with GFP-RuvA. DSBs 
were evaluated 48h after transfection by neutral Comet assay. (B) The presence of 
53BP1 nuclear foci was evaluated by IF 48 h after transfection. The graph shows the 
fold increase of 53BP1 foci-positive cells over the untransfected cells.Data are 
presented as mean ± standard error (SE) from three independent experiments. *P ≤ 
0.5; ****P ≤ 0.001,ANOVA test. (C) Representative microscopy fields are presented: 
53BP1 antibody (green or red), GFP-RuvA and nuclear DNA was counterstained by 
DAPI (blue). 
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Figure 26 Flow cytometry analysis of cell cycle progression and DNA damage. (A) 
Asynchronously proliferating MRC5 cells were treated with a 1 h 5-Bromo-2´-
Deoxyuridine (BrdU) pulse, stained for BrdU and analyzed by quantitative flow 
cytometry. Density plots depict mean BrdU  intensities. PI staining was used to 
determine DNA content. (B) Asynchronously proliferating MRC5 cells were stained 
for γ-H2AX and analyzed by quantitative flow cytometry. Dot plots depict mean γ-
H2AX intensities versus total nuclear DNA (PI intensities). The table shows the 
percentage of γ-H2AX-positive cells in each phase of cell cycle from a representative 
experiment. 
Figure 27 Phosphorylation status of S87 affects MUS81 catalytic activity. (A) 
Oligomer sequences used to build the synthetic nicked-Holliday Junction (nHJ) 
substrate. One oligonucleotide (d) is 5’ 6-FAM end-labelled. (B) FLAG-MUS81wt, 
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FLAG-MUS81S87A and FLAG-MUS81S87D immunoprecipitated from 
asynchronous and Noc-treated cells were incubated with the indicated nHJ substrate 
(50nM). 5’ end fluorescent label is indicated as a green dot. Reaction was performed 
at 30°C for 90 min and the DNA substrates were analyzed by neutral PAGE. The 
unbound anti-FLAG beads (1st lane) were used as negative control. Quantification of 
cleaved products, expressed as percentage of the total substrate, is reported in the 
graph at the bottom of the panel. (C) The same FLAG-MUS81 immunoprecipitates 
used in the nuclease assay were analysed by Western blotting for the indicated 
proteins. 
5. Phosphorylation at Serine 87 induces premature mitotic entry 
through unscheduled MUS81 function in S-phase 
Recent data evidenced that inhibition of WEE1 leads to premature 
activation of the MUS81 complex, because it releases CDK1 
inhibition and stimulates phosphorylation of SLX4, licensing the 
formation of the MUS81/SLX4 complex in S-phase, and inducing 
uncontrolled progression in mitosis of unreplicated cells (Duda, et al., 
2016). We show that phosphorylation of MUS81 at S87 is crucial to 
MUS81-EME1 activation. Hence, we analysed if abrogation of S87 
phosphorylation could revert the effect of WEE1 inhibition. To 
analyse premature mitotic entry from S-phase, we pulse-labelled a  
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subset of replicating cells with BrdU, chased them in BrdU free 
medium in the presence or absence of WEE1 inhibitor, and analysed 
progression of the BrdU-positive population through the cell cycle by 
bivariate flow cytometry (Fig. 28). Under unchallenged conditions, no 
substantial difference in the progression of the labelled S-phase 
population was observed in wild-type andMUS81S87A cells. 
However, a higher percentage of BrdU-labeled G1 cells (G1*), a sign 
of a faster transit through the cell cycle, was observed in MUS81S87D 
cells after 5 h of chase as compared with the wild-type ones (Fig. 28B 
and C). As expected, in wild-type cells, inhibition of WEE1 (WEE1i) 
resulted in a faster progression from S-phase to mitosis, resulting in a 
strong increase of BrdU-positive cells in the subsequent G1- phase. In 
contrast, and interestingly, expression of the unphosphorylable S87A-
MUS81 protein completely reverted the effect of WEE1i on cell cycle.  
Surprisingly, a reduction of the number of BrdU-positive G1 cells 
after WEE1 inhibition was also observed in cells expressing the 
phosphomimetic S87D-MUS81 mutant. Consistent results were also 
obtained by analysing progression of a BrdU-pulse labelled population 
to mitosis by anti-pS10H3/BrdU double immunofluorescence (Fig. 
28D).  
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Indeed, treatment of wild-type cells with WEE1i greatly increased the 
number of BrdU-positive cells accumulated in mitosis by Noc, while 
expression of the S87A-MUS81 mutant reverted the phenotype. Of 
note, inhibition of WEE1 failed to increase the fraction of BrdU-
positive mitosis detected in MUS81S87D cells. Inhibition of CDK1 
can prevent unscheduled activation of MUS81 by WEE1i (Duda, et 
al., 2016). As shown in Fig. 29A, inhibition of CDK1 reverted the 
progression of BrdU-labelled S-phase cells to G2/M and the 
subsequent G1, which is stimulated by WEE1 inhibition, irrespective 
of the presence of a mutant MUS81 protein. Suppression of the 
WEE1i-induced premature mitotic entry is also obtained with EME2 
or SLX4 depletion (Duda, et al., 2016). In wild type cells, depletion of 
EME2 reduced the unscheduled progression from S to G2/M and G1, 
which is stimulated by WEE1 inhibition, but only partially (Fig. 29B 
and C). Of note, depletion of EME2 reduced the limited progression 
from S toG2/M and G1 observed in the S87A-MUS81mutant, while 
was largely ineffective in modulating the phenotype of the S87D-
MUS81 mutant, either in the absence or in the presence ofWEE1i. A 
consistent effect was observed when we analysed the S-M progression 
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by anti-pS10H3/BrdU double immunofluorescence (Fig. 29D). 
Depletion of EME2 reduced the premature S-M transit induced by 
WEE1i in wild-type cells, while it minimally affects the MUS81S87D 
phenotype. As expected, depletion of SLX4 completely reverts 
premature SM transit independently on the deregulated S87 
phosphorylation of MUS81 (Fig. 29D). These results indicate that 
phosphorylation of MUS81 by CK2 is absolutely required for the 
pathological S/M transit associated to WEE1 inhibition and 
deregulated phosphorylation of SLX4. Moreover, they suggest that the 
presence of a constitutively-activeMUS81 complex and WEE1 
inhibition does not synergize, but rather result in an apparent slow-
down of the cell cycle.  
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Figure 28 Premature mitotic entry mediated by unscheduled MUS81 function in S-
phase depends on phosphorylation at S87. (A) Experimental workflow. (B) S-phase 
cells were pulse-labelled with BrdU and released in free medium for 5 h, in the 
presence or not of the WEE1 inhibitor MK-1775 (WEE1i). Progression of S-phase 
cells through the cell cycle was analysed by bivariate flow cytometry. The scheme 
indicates how each population was assigned. The star (*) denotes S-labeled, BrdU-
positive, populations. Density plots depict mean BrdU intensities versus total nuclear 
DNA intensities (PI). The percentage of cells found in each phase of cell cycle is 
indicated. (C) The graph shows the percentage of cells in G2/M*, S* and G1* phase 
treated or not with WEE1i inhibitor MK-1775, relative to scatterplots in (B). (D) 
Immunofluorescence analysis of S-M progression. S-phase cells were labelled with a 
1 h BrdU pulse, and released in nocodazole to accumulate mitosis. Cells accumulated 
in mitosis for 16 h, in presence or not of WEE1i, and immunostained using anti-BrdU 
and pS10H3 antibodies. Data are presented as mean ± standard error (SE) from three 
independent experiments. **P < 0.1; ns = not significant, ANOVA test.  
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Figure 29 Progression analysis of the BrdU-positive cells through the cell cycle by 
bivariate flow cytometry. In A) Asynchronously proliferating MRC5SV40 
complemented with MUS81WT and S87 phosphorylation mutant cells were treated 
with a 1h 5-Bromo-2´-Deoxyuridine (BrdU) pulse, release in free medium for 5h, 
treated or not with WEE1 inhibitor MK-1775 (500nM) and CDK1 inhibitor as 
indicated and stained for BrdU. The graph shows the analysis by quantitative flow 
cytometry. Scatterplots depict mean BrdU intensities versus total nuclear PI 
intensities. The graph shows the percentage of cells in G2/M*, S* and G1* phase 
treated or not with WEE1i and CDK1i, relative to scatterplots. (B) Western blot of 
EME2 interference in MRC5SV40 complemented with MUS81WT and S87 
phosphorylation mutant cells. Lamin B1 was used as loading control. (C) Analysis by 
quantitative flow cytometry performed as in (A) with cells treated with WEE1i and/or 
transfected with siEME2. The graph shows the percentage of cells in G2/M*, S* and 
G1* phase treated or not with WEE1i and with siEME2, relative to scatterplots.  
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(D) Immunofluorescence analysis of S-M progression. S-phase cells were labelled 
with a 1h BrdU pulse and released in nocodazole to accumulate mitosis. Cells 
accumulated in mitosis for 16h, in presence or not of WEE1i, and immunostained 
using anti-BrdU and pS10H3 antibodies. Data are presented as mean ± standard error 
(SE) from three independent experiments. 
6. Regulated phosphorylation of MUS81 at Serine 87 is essential 
to prevent accumulation of genome instability 
Downregulation of MUS81 induces mitotic defects and accumulation 
of bulky anaphase bridges as a consequence of poor resolution of 
replication/recombination intermediates prior to mitosis (Garner et al., 
2013; Matos, Blanco, & West, 2013a). Our data suggest that S87 
phosphorylation of MUS81 may affect function of the complex in 
mitosis. Hence, we analysed the presence of bulky anaphase bridges  
in cells expressing the wild-type MUS81 or the two S87 
phosphomutants, exposed or not to a low-dose Aph (Fig. 30A). Under 
unperturbed cell growth, the number of anaphase cells with bulky 
chromatin bridges was found elevated, albeit modestly, in 
bothMUS81-depleted cells and in cells expressing the 
unphosphorylable S87A-MUS81 protein. In contrast, very few 
anaphases with bulky chromatin bridges were found in cells 
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expressing the phosphomimic mutant of MUS81. In Aph-treated cells, 
the percentage of anaphases with bulky chromatin bridges was similar 
among cell lines, except those expressing the phosphomimic 
S87DMUS81mutant, which showed less anaphase bridges. These data 
support the functional role of S87 phosphorylation of MUS81 in 
mitosis. Nevertheless, deregulation of S87 phosphorylation causes 
DNA damage in S-phase being involved in premature formation of 
theMUS81/EME1/SLX4 complex. Hence, we investigated whether 
expression of the S87 unphosphorylable or phosphomimic 
MUS81mutant might undermine genome integrity. To this end, we 
analysed the number and type of chromosomal damage in metaphase 
spreads from cells treated or not with a low-dose Aph, which induces  
a mild replication stress that the MUS81 complex contributes to fix. 
As shown in Fig. 30B, mild replication stress increased the frequency 
of chromosome breakage in wild-type cells. As expected, the number 
of chromosome breaks detected on mild replication stress was slightly 
reduced upon MUS81 downregulation while, unexpectedly, it was 
only slightly enhanced by expression of the S87 unphosphorylable 
MUS81mutant. In contrast, the frequency of chromosome breakage  
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was significantly higher in cells expressing the S87D-MUS81 mutant 
already under unperturbed replication and increased further upon 
treatment with Aph. Interestingly, MUS81S87D cells also showed 
complex chromosome aberrations, such as chromatid exchanges and 
pulverized metaphases, which were otherwise absent in wild-type or 
MUS81S87A cells (Fig. 30C). The unscheduled targeting of 
replication forks by the MUS81 endonuclease triggered by chemical 
inhibition of WEE1 is sufficient to induce chromosome pulverization 
(Duda et al., 2016). As we show that S87 phosphorylation 
predominates onWEE1 inhibition (Fig. 28), we evaluated if 
chromosome pulverization observed in cells treated with the WEE1i 
might be modulated by the presence of the two S87 phosphomutants 
of MUS81. As reported in Fig. 30D, inhibition of WEE1 resulted in 
the appearance of pulverized metaphases in wild type cells, and this 
phenotype greatly increased in response to Aph. As expected, the 
percentage of pulverisation was significantly reduced in MUS81-
depleted cells respect to the wild-type, especially after Aph treatment 
(Fig. 30D). Interestingly, WEE1i-dependent chromosome 
pulverisation was suppressed also by expression of the S87A-MUS81 
mutant (Fig. 30D).  
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Conversely, MUS81S87D cells showed chromosome pulverization 
even in absence of WEE1i, and the phenotype was significantly 
enhanced in its presence, suggesting that pharmacological override of 
cell cycle control and unscheduled targeting of replication forks by the 
MUS81/EME1 complex act synergistically. Interestingly, while 
depletion of EME2 partially rescued the pulverization phenotype 
associated to inhibition of WEE1 in wild type cells it failed to 
modulate the pulverisation detected in MUS81S87D cells (Fig. 31A 
and B), confirming that expression of the phosphomimeticMUS81 
mutant preferentially engages the MUS81/EME1 complex. Therefore, 
we conclude that phosphorylation of MUS81 S87 by CK2 is required 
to support function of the MUS81 complex during resolution of 
intermediates accumulating under mild replication stress, but also that 
loss of regulated phosphorylation strongly undermines genome 
integrity.  
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Figure 30 Regulated phosphorylation of MUS81 at S87 is essential to prevent 
accumulation of genome instability. (A) Analysis of the bulky anaphases bridges 
inMUS81 phosphomutants treated with a low-dose Aphidicolin (Aph). The graph 
shows the fractions of mitotic cells with bulky anaphase bridges. Error bars indicate 
SE; n=3 (>50 mitotic cells were analyzed in each population).Data are presented as 
mean±standard error (SE) from three independent experiments. *P < 0.5; **P < 0.1; 
***P <0.01, ANOVA test. Significance is reported compared to the wild-type. 
Representative images of single anaphases from the phosphomimetic MUS81 mutant 
are shown. Arrows indicate bridges. (B) Experimental scheme for evaluation of 
chromosomal aberrations is shown. Dot plot shows the number of chromosome 
aberrations per cell. Data are presented as means of three independent experiments. 
Horizontal black lines represent the mean ± SE. (ns, not significant; **P < 0.01; ***P 
< 0.001; ****P < 0.0001 two-tailed Student’s t test). Representative Giemsa-stained 
metaphases are given. Arrows in red indicate chromosomal aberrations. (C) Analysis 
of the frequency of metaphase spreads with chromatid exchanges in cells treated and 
processed as in (B). Bar graph shows the percentage of chromatid exchanges per 
metaphase cell. Data are presented as means of three independent experiments. 
Horizontal black lines represent the mean ± SE. A representative Giemsa-stained 
metaphase with chromatid exchanges is given. (D) Experimental scheme for 
evaluation of chromosomal aberrations is shown. Bar graph shows the frequency of 
pulverized metaphases per metaphase cell. Data are presented as means of three 
independent experiments. Error bars representing standard errors are not shown or 
clarity but are <15 of the mean (*P < 0.5; **P < 0.01; ***P < 0.001; two-tailed 
143 
 
Student’s t test). Representative Giemsa-stained metaphases are given for both normal 
and pulverized phenotype. Significance is reported compared to the wild-type. 
 
 
Figure 31 Depletion of EME2 does not prevents chromosome pulverization induced 
by expression of the S87 phosphomimetic MUS81 mutant. (A) Western blot of EME2 
interference in MRC5SV40 complemented with MUS81WT and S87 phosphorylation 
mutant cells. Lamin B1 was used as loading control. B) Bar graph shows the frequency 
of pulverized metaphases per metaphase cell. Data are presented as means of three 
independent experiments. Error bars representing standard errors are not shown or 
clarity but are < 15 of the mean (*, p<0.5 **, p < 0.01; ***, p < 0.001; two-tailed 
Student’s t test). 
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PART II  
1.Regulation of the mitotic function of MUS81 by CK2 
sustains viability in cells lacking BRCA2 
Since we know that proliferation of BRCA2-deficient cells relies on 
the MUS81 complex to reduce replication stress in S-phase and to 
prevent detrimental consequences of under-replicated DNA in mitosis 
(Lai et al., 2017), we asked how much of the pro-survival role of the 
MUS81 complex depends on its mitotic function. To this aim, we took 
advantage from regulatory mutants of MUS81 that affect proper 
activation in the M-phase of the cell cycle by the CK2 kinase (Palma, 
Pugliese et al., 2018). MRC5 fibroblasts stably-depleted for MUS81 
and complemented with the wild-type MUS81 (MUS81WT), its CK2-
unphosphorylable (MUS81S87A) or CK2-phosphomimetic 
(MUS81S87D) mutant were transfected with siRNA targeting BRCA2 
(Fig.32A). Forty-eight hours after transfection, cells were seeded at 
low-density to analyse, by clonogenic assay, whether a loss of 
regulated MUS81 complex function in M-phase affected proliferation 
and viability in the absence of BRCA2. As expected, concomitant loss 
of MUS81 and BRCA2 caused a significant decrease in cell survival 
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compared to BRCA2 depletion alone (MUS81wt) (Lai et al., 2017) 
(Fig. 32B-C). A less prominent decrease of cell proliferation was also 
observed in cells lacking BRCA2 and expressing MUS81S87A, but not 
in cells expressing MUS81S87D (Fig. 32B-C). To determine whether 
BRCA2 depletion affected S87MUS81 phosphorylation, we 
performed anti-pS87MUS81 immunofluorescence in asynchronous 
cultures of MUS81WT cells (untr) or in cultures enriched in M-phase 
by nocodazole (NOC). Anti-pS87MUS81 immunofluorescence was 
coupled with EdU detection to identify any abnormal activation of the 
MUS81 complex in S-phase (Fig. 32D). As expected, MUS81 
phosphorylation at S87 by CK2 was barely detectable in S-phase cells 
whereas it was abundant in Noc-arrested cells (Fig. 32D). 
Interestingly, depletion of BRCA2 did not induce any unscheduled 
phosphorylation of MUS81 at S87 in S-phase or increased its normal 
mitotic modification (Fig. 32D).  Collectively these results confirm the 
important role of MUS81 in BRCA2-depleted cells and suggest that 
phosphorylation of S87 by CK2 is important to sustain proliferation in 
BRCA2 deficient cells.  
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Figure 32 Regulation of the mitotic function of MUS81 by CK2 sustains viability in 
cells lacking BRCA2. (A) Analysis of protein depletion by Western blotting in MRC5 
SV40 cells after transfection with control siRNAs or siBRCA2. Immunoblotting was 
performed 48 h after transfection using the indicated antibodies. Lamin B1 was used 
as loading control. (B) Cells treated as in A were plated 48h after transfection for 
clonogenic assay. Colonies were stained after 10-14 days. Error bars represented s.d. 
(n=4). *P≤0.5, **** P≤0.001, ANOVA test. (C) Representative images of GIEMSA 
stained colonies. (D) MUS81 phosphorylation by anti-pS87MUS81 
immunofluorescence (red) was evaluated inMRC5 SV40 shMUS81 and MUS81wild-
type stably complemented cells transfected with siCTRL or siBRCA2 and 
previouslyexposed to a 30min EdU pulse to mark S-phase cells (green). Nuclei were 
depicted by DAPI staining (blue).  Nocodazole (NOC)  was used as control of cells 
accumulated in M-phase. The WB shows actual depletion levels, and images are 
representative of IF. The graph shows quantification of pS87MUS81 antibody signal 
intensities. 
2. DNA damage in BRCA2-depelted cells correlates with 
phosphorylation status of S87-MUS81 and influence cell cycle 
progression  
Our data show that abrogation of the mitotic function of the MUS81 
complex through loss of CK2-dependent regulation of MUS81 is 
sufficient to reduce proliferation of BRCA2-deficient cells  
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recapitulating downregulation of MUS81 by RNAi. Since loss of 
BRCA2 induces accumulation of DNA breakage even under 
unperturbed cell growth and recent works demonstrate that DSBs 
formation after HU is prevented by MUS81 depletion in the absence 
of BRCA2 (Feng and Jasin 2017; Lemaçon et al. 2017b), we reasoned 
that BRCA2-deficient cells might require mitotic MUS81 function to 
induce DNA breaks for resolution of persistent replication 
intermediates. To this aim we performed neutral Comet assay to detect 
DSBs formation in shMUS81 cells complemented with the mitotic 
phosphomutants of MUS81 and depleted or not of BRCA2 (Fig. 33B).  
As expected, the analyses revealed few DSBs in cells depleted of 
MUS81 or in cells complemented with the wild-type MUS81 protein 
(Fig. 33B).  Similarly, few DSBs were found in shMUS81 cells 
complemented with the S87A MUS81 mutant, whereas, a significant 
increase in the amount of DSBs was detected in cells expressing the 
S87D phosphomimetic mutant of MUS81 (Fig 33B). As expected, 
depletion of BRCA2 in wild-type cells increased the amount of DSBs, 
which were not detected in the shMUS81 cells (Fig. 33B). 
Interestingly, the increased formation of DSBs associated with  
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downregulation of BRCA2 was neither affected by loss of S87 
MUS81 phosphorylation nor by its constitutive activation (Fig. 33B).  
To further investigate on the functional role of MUS81 
phosphorylation at S87 in BRCA2-depleted cells we next analysed the 
level of H2AX phosphorylation, another diagnostic sign of DNA 
damage, by immunofluorescence. To discriminate between H2AX 
phosphorylation occurring in S-phase or in other phases of the cell 
cycle, we coupled anti-γ-H2AX immunofluorescence with detection 
of EdU incorporation. Consistently with what observed by neutral 
Comet assay, anti-γ-H2AX immunofluorescence confirmed that 
BRCA2 depletion increased DNA damage in wild-type cells (Fig. 
33C). Although downregulation of MUS81 or the expression of 
MUS81S87A resulted in low level of γ-H2AX-positive cells, the 
BRCA2-depletion surprisingly induced an accumulation of DNA 
damage especially in EdU-positive cells (Fig. 33C). By contrast, 
MUS81S87D failed to further stimulate DNA damage in absence of 
BRCA2 but changed dramatically the ratio between the total number 
of γ-H2AX- and EdU/γ-H2AX-positive cells (Fig. 33C). To evaluate 
whether DNA damage accumulation could lead to cell cycle defects,  
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we performed bivariate flow cytometry analysis of replicating cells 
pulse-labelled with 1h of BrdU (Fig. 34A). No overt difference in cell 
cycle was observed between the MUS81 mutant cell lines when 
BRCA2 was depleted (Fig. 34B). This result led us to investigate if 
concomitant BRCA2-depletion and abrogation of mitotic MUS81 
function could affect progression from S to M-phase (S-M transition). 
To this end, we combined anti-pS10-H3 immunostaining with 
detection of EdU incorporation in S-phase cells (Fig. 34C). Depletion 
of BRCA2 halved the percentage of MUS81WT cells entering mitosis 
from S-phase in the 8h chase period after pulse-labelling with EdU 
(Fig. 34D), confirming that loss of BRCA2 delays S-phase transit 
and/or induces accumulation in G2, to pause cell cycle for preserve 
genetic stability  (Patel et al., 1998; Yu et al., 2000). In contrast, the 
delayed S-M transit induced by BRCA2 depletion did not occurred in 
absence of MUS81 or upon expression of the unphosphorylable S87A 
mutant (Fig. 34D). Surprising, a strongly-delayed S-M progression 
was apparent in MUS81S87D cells and this phenotype was exacerbated 
after BRCA2-depletion (Fig. 34D). Altogether, these results support 
the idea that MUS81 activity in M-phase is required for a correct S-M  
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transition in BRCA2-deficient cells. Loss of MUS81 induces a 
replication fork progression defects in BRCA2-depleted cells (Lai et 
al., 2017). To determine whether increased DNA damage and delayed 
cell cycle progression observed in absence of MUS81 or upon 
expression of the unphosphorylable S87A mutant could correlate with 
defects in fork progression, we measured replication rates using DNA 
fibre assays. Ongoing forks were labelled using two consecutive 
IdU/CldU pulses of 15min to reduce the effect of fork degradation on 
replication tract length. Indeed, under our experimental conditions, 
depletion of BRCA2 did not significantly affect the length of 
replication tracks (Fig. 34E). According to previous studies(Sarbajna 
et al., 2014; Lai et al. 2017), MUS81 depletion had no effect on fork 
progression if BRCA2 is present, while its depletion combined with 
that of  BRCA2 resulted in shorter replication track lengths (Fig. 34E). 
Of note, although expression of each MUS81 phosphorylation mutant 
did not significantly alter the replication track length compared with 
cells expressing wild-type MUS81, concomitant depletion of BRCA2 
reduced replication track lengths in the presence of the 
unphosphorylable S87A mutant (Fig. 34E). Surprisingly, this did not  
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happen in the MUS81S87D, in which the depletion of BRCA2 failed to 
influence fork velocity. These results indicate that concomitant loss of 
MUS81 or its mitotic phosphorylation at S87 can enhance greatly 
DNA damage in the absence of BRCA2, which seems unrelated to 
DSBs processing, but possibly linked with reduced fork velocity and 
inability to slowdown S-M transition. 
 
153 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33 DNA damage in BRCA2-depelted cells correlates with phosphorylation 
status of S87-MUS81. (A) Analysis of protein depletion by Western blotting in MRC5  
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SV40 cells after transfection with control siRNAs (siCtrl) or siBRCA2. 
Immunoblotting was assessed 48 h after transfection using the appropriate antibodies. 
Lamin B1 was used as loading control. (B) Formation of DSBs after BRCA2-
depletion. Cells were transfected with a Ctrl siRNA or with a siRNA against BRCA 
and, 48h afetr DSBs were evaluated by neutral comet assay. Data are presented as 
mean±SEM from three independent experiments. Statistical analysis was performed 
by two-way ANOVA test: ns, not significant, *P≤0.5, **** P≤0.001. Representative 
images of Comets are presented in the panel. (C) Analysis of the level of DNA damage 
during replication. Cells in S-phase were labelled by an EdU pulse and the graph 
shows the percentage of EdU  and anti-γ-H2AX  positive cells.  
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Figure 34 Phosphorylation status of S87-MUS81 in BRCA2-depelted cells influence 
cell cycle progression. (A) Experimental scheme for quantification of G1, S and G2/M 
cell populations in asynchronous cultures of BrdU-labelled cells. PI, propidium 
iodide. of chromosomal aberrations is shown.  (B) The graph shows the percentage of 
cells in G1, S and G2/M phase transfected or not with siBRCA2 as in (A).  
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(C) Experimental scheme used to study the S-M transition in MUS81 phosphorylation 
mutants after BRCA2-depletion and Nocodazole accumulation. (D) 
Immunofluorescence analysis of S-M progression. S-phase cells were labelled with 
EdU pulse, and released in nocodazole to accumulate mitosis as in (C). Cells 
accumulated in mitosis, depleted or not with siBRCA2, and immunostained using 
anti-EdU and pS10H3 antibodies. (E) Experimental scheme of dual labelling 
replication assay for DNA fibres. Red tract: CldU; green tract: IdU. Dot plot showing 
the IdU+CldU tract length (µm) of ongoing forks in single DNA fibres from MRC5 
SV40-derived cells stably non expressing MUS81, MUS81 wild-type and the two 
phosphomimetic forms (S87A and S87D) depleted or not with siBRCA2. The length 
of the tract was measured in at least 100 well isolated DNA fibres from three 
independent experiments. Mean values are represented as horizontal black lines ±SE 
(ns = not significant; P> 0.05; **P< 0.01; ***P< 0.001; ****P < 0.0001; ANOVA 
test).  
 3. The absence of BRCA2 leads to formation of mitotic 
chromosome bridges in constitutive active MUS81 mutant 
Since unresolved DNA and chromatin bridges during anaphase and 
telophase can induce cytokinesis defects, DNA segregation 
abnormalities might contribute to the cytokinetic defects in BRCA2 
deficient cells (Choi et al., 2012; Daniels et al., 2004; Mondal et al., 
2013). We recently demonstrated the important functional role of S87 
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phosphorylation in mitosis for the resolution of intermediates at under-
replicated regions (Palma, Pugliese et al., 2018). Thus, we want to test 
whether S87MUS81 and BRCA2-depletion could impact on 
chromosome segregation. As expected, quantification of DAPI-
positive anaphase bridges revealed that MUS81 inactivation in 
BRCA2-depleted cells led to a higher percentage of cells with DAPI-
positive bridges compared to BRCA2 depletion alone (Fig. 35A). In 
agreement with our previous data (Palma,Pugliese et al., a 2018), the 
number of bulky bridges was found higher in both shMUS81 and 
MUS81S87A cells and, notably, this phenotype was exacerbated when 
BRCA2 was depleted (Fig. 35B). Interestingly, a higher number of 
anaphase cells with chromatin bridges were found also in the 
phosphomimic mutant of MUS81 after BRCA2 depletion. Of note, the 
increase of DAPI-positive anaphase bridges after BRCA2 depletion 
was less in cells depleted of MUS81 or expressing the S87A 
unphosphorylable mutant than in cells expressing the wild-type or 
phosphomimetic MUS81 protein. The elevated levels of DAPI-
positive bridges suggested possible cytokinesis-related defects. To test 
this hypothesis, we analysed the frequency of multinucleated cells in  
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BRCA2-deficient cells expressing the wild-type MUS81 or its mitotic 
regulatory mutants by anti-α-tubulin immunofluorescence. A general 
increase in the frequency of multinucleated cells was seen in cells 
expressing the S87 phosphomutants of MUS81 or in cells knocked-
down for MUS81 (Fig. 35C-D). In the absence of BRCA2, the number 
of multinucleated cells increased further in wild-type or in shMUS81 
cells while it was marginally affected in MUS81S87A or MUS81S87D 
cells (Fig. 35C-D). This indicate that loss of MUS81 or its mitotic 
function is required to counteract cytokinesis failure in BRCA2-
deficient cells although a MUS81 deregulated activity is sufficient to 
increase segregation defects per se.  Since defective resolution of 
replication intermediates correlates with persisting DNA damage in 
the next cell cycle, we next analysed the accumulation of 53BP1 
nuclear bodies (NBs) in Cyclin-A-negative G1 cells after 
immunostaining in cells expressing the wild-type form of MUS81 or 
its S87 phosphorylation mutants and BRCA2-depleted. Interesting, 
and consistently with Lai and colleagues (Lai et al., 2017), the number 
of 53BP1-positive G1 cells increased after BRCA2-depletion in cells 
expressing the wild-type MUS81 but also in MUS81-deficient cells or  
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in the S87A-MUS81 mutant (Fig. 35E). Surprisingly, the 
constitutively active MUS81 mutant, MUS81-S87D, presented a 
reduced number of 53BP1 NBs upon BRCA2 depletion as compared 
with the control-depleted cells (Fig. 35E). Therefore, these results 
indicate that when mitotic activity of MUS81 is deregulated, the 
absence of BRCA2 worsens the levels of chromosome mis-
segregation. However, BRCA2-depletion only minimally affects the 
persistence of DNA lesions or under-replicated regions observed in 
the unphosphorylable MUS81 mutant.  
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Figure 35 The absence of BRCA2 leads to formation of mitotic chromosome bridges 
in constitutive active MUS81 mutant. (A) Control of protein depletion by Western 
blotting in MRC5 SV40 cells after transfection with control siRNAs or siBRCA2. 
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Immunoblotting was performed using the relevant antibodies. Lamin B1 was used as 
loading control. (B) Analysis of the bulky anaphases bridges in MUS81 
phosphomutants transfected or not with siBRCA2. The graph shows the fractions of 
mitotic cells with bulky anaphase bridges. Error bars indicate SE; n=3(>50 mitotic 
cells were analyzed in each population). Data are presented as mean±standard error 
(SE) from three independent experiments. *P< 0.5; **P< 0.1; ***P<0.01, ANOVA 
test. Significance is reported compared to the wild-type. Representative images of 
single anaphases from the phosphomimetic MUS81 mutant are shown. Arrows 
indicate bridges. (C) MUS81 phosphomimetic mutants were transfected with control 
or BRCA2. Representative images of cells stained with an α-tubulin antibody (green) 
after 48h after transfection are shown. DNA was counterstained with DAPI. (D) 
Quantification of the frequency of multinucleated cells in asynchronous cultures 
treated as in (C). Error bars represent s.d. (n=3). ns: non significant; *P<0.05; 
**P<0.01; ***P<0.001 (ANOVA-test). (E) Quantification of the frequency of cyclin 
A-negative G1 cells containing >4 53BP1 nuclear bodies. Representative image of 
fluorescence cells after 48h after transfection stained with anti-53BP1 (green) are 
shown in the panel, nuclear DNA was counterstained by DAPI. The graph shows 
quantification of the 53BP1-negative Cyclin A-cells. Data are mean values from three 
independent experiments. Statistical analysis was performed by Student’s t-test. ns: 
not significant; *P<0.05; **P<0.01; ***P<0.001.  
162 
 
4. Different DNA repair pathways sensitize S87MUS81 
phosphorylation mutant in BRCA2 deficient cells  
Cells with impaired BRCA2 function and consequent HR deficiency 
are hypersensitive to cross-linking agents, such as cisplatin, and to 
poly(ADP-ribose) polymerase (PARP) inhibitors, which are being 
extensively explored as cancer therapeutics (Feng and Jasin 2017b; 
Bryant et al. 2005; Chan et al. 2011; Farmer et al. 2005; Murai et al. 
2013). This profound hypersensitivity of BRCA2-mutant cells to 
PARP inhibitors has become an emerging therapeutic paradigm 
known as synthetic lethality. As loss of MUS81 or of its mitotic 
function reduced proliferation in BRCA2-depleted cells (Fig. 32B), 
we wanted to determine whether blocking MUS81 activation in 
mitosis would modify sensitivity to the PARP1i Olaparib. Therefore, 
we performed clonogenic survival assays in cells downregulated for 
MUS81 or expressing the wild-type form of MUS81 or its S87 
phosphorylation mutants in absence of BRCA2. Treatment with 
Olaparib reduced cell survival in all cell lines but at different extent 
with cells downregulated of MUS81 or expressing the S87D mutant 
being the less sensitive (Fig. 36B). As expected, depletion of BRCA2  
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synergized with that of MUS81 or its mitotically-inactive mutant 
S87A. Interestingly, although concomitant depletion of BRCA2 and 
inhibition of PARP1 lead to further decrease of cell survival in wild-
type MUS81 cells, the reduction of cell survival was less significant 
in absence of MUS81 or in MUS81S87A cells. Surprisingly, expression 
of the constitutively-active S87D-MUS81 mutant abrogated Olaparib 
sensitivity associated to BRCA2-depletion. This striking phenotype 
prompted us to analyse further the effect of BRCA2-depletion in cells 
having a constitutively-active MUS81 protein. It was demonstrated 
that genetic ablation or inhibition of key components of pathways 
involved in DSBs repair such as alt-NHEJ suppressed aberrant 
phenotypes in BRCA2-depleted cells (Han et al.,2017). The 
phosphomimetic S87D MUS81 mutant generates spontaneous DNA 
damage in S-phase (Palma,Pugliese et al., 2018), which is apparently 
unaltered by BRCA2 deficiency (Fig. 33B-C). Since PARP1 
inhibition should synergize with DNA damage left unrepaired by HR 
because of BRCA2 loss, we wondered whether inhibition of alt-NHEJ 
by the ligaseI/III inhibitor L67 (Chen et al., 2009) affected clonogenic 
cell survival of BRCA2-depleted cells expressing the different 
MUS81 phosphomutants.  
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As reported in Fig. 36C, concomitant BRCA2-depletion and L67 
treatment resulted in a significant reduction in cellular viability in 
MUS81S87D cells compared to BRCA2-depletion or L67 treatment 
alone. In contrast, we observed barely-significant differences in cells 
expressing wild-type MUS81 and a slight increase in the MUS81S87A 
cells. Of note, the reduction in cell survival observed in MUS81S87D 
cells depleted of BRCA2 after L67 treatment is comparable to that 
associated with Olaparib treatment in wild-type cells after BRCA2 
down-regulation. These results suggest that MUS81S87D may promote 
Olaparib resistance in BRCA2-deficient cells, indicating that the 
functionality of MUS81 complex affects sensitivity of BRCA2-
deficient cells to Olaparib and suggest that the targeted inhibition of 
particular DNA repair pathways may be useful to exploit BRCAness 
of human tumours and overcome resistance to PARP1i.  
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Figure 36 Different DNA repair pathways sensitize S87MUS81 phosphorylation 
mutant in BRCA2 deficient cells. (A) Western blotting analysis shows level of 
BRCA2 protein after transfection with siRNA. Lamin B1 was used as loading. (B) 
MRC5 SV40-derived cells stably depleted of MUS81 and complemented with 
MUS81 wild-type or the two phosphomimetic forms (S87A and S87D were 
transfected with the indicated siRNAs or untransfected to perform clonogenic assay.  
Twenty-four hours later, cells were treated with 10 µM olaparib (PARP inhibitor) and 
24h after were  plated at low cell density into 6-well plates. Cells were grown for 10 
days, and colonies were stained. Data are presented as mean ± SD (n=3). Statistical 
significance, *P<0.05; **P<0.01; ***P<0.001; ns: not significant) was calculated 
with Tukey multiple comparison test using one-way ANOVA. (C) Similar analyses 
were conducted treating cells after 24h after transfection with siBRCA2 with 0,5µM 
L67 inhibitor. Error bars represent s.d. (n=3). *P<0.05; **P<0.01; ***P<0.001; ns: 
not significant (ANOVA-test).  
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DISCUSSION  
CK2 regulates S87 MUS81 phosphorylation in mitosis and after 
replication stress 
The structure-specific endonuclease MUS81/EME1 plays important 
roles in the resolution of recombination intermediates, however, its 
function needs to be carefully regulated to avoid an unscheduled 
targeting intermediates during DNA replication, which may result in 
genome instability. Regulation of the MUS81 complex has been 
mostly investigated in yeast, and several publications demonstrated 
that cell cycle-dependent phosphorylation of the Mms4EME1 subunit 
by Cdc28CDK1 or Cdc5PLK1 ensures activation of the MUS81 
complex in G2/M (Dehé et al., 2013; Gallo-Fernández et al., 2012; 
Matos et al., 2011a). In yeast, the MUS81 complex can be also 
regulated by checkpoint kinases in response to DNA damage (Dehé et 
al., 2013; Kai et al., 2005). In human cells, a cell cycle-dependent 
regulation of the MUS81 complex has been indirectly inferred from 
association with PLK1, and the presence of phosphorylated isoforms 
of EME1 in mitosis (Svendsen et al., 2010a; Wyatt et al., 2013). The 
functional role of such events and the identity of the targeted residues 
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are almost unknown, and only recently a mechanistic link between 
CDK1-dependent phosphorylation and activation of the human SLX4-
MUS81-EME2 axis has been revealed (Duda, et al., 2016). However, 
in most cases, the phenotype associated with loss ofMUS81 complex 
regulation has been deducted from inhibition of cell cycle-related 
kinases, such as CDK1 or PLK1, so that the observed effect may 
derive also from perturbation of cell cycle progression per se or from 
altered function of other targets. Here, we find that the biological 
function of theMUS81-EME1 complex in human cells is positively 
regulated by CK2, which phosphorylates Serine 87 (S87) of the 
MUS81 subunit in mitosis. Interestingly, phosphorylation at S87 
increases from late G2 to prophase and disappears as soon as cells 
proceed to metaphase. Activation of the MUS81-EME1 complex 
during prophase or pro-metaphase has been hypothesised from 
interaction with its key partners using synchronised cells (Duda, et al., 
2016). Our data on S87 phosphorylation confirm that the human 
MUS81-EME1 complex becomes active in late G2 and early mitosis 
and suggest that pS87MUS81 is excluded from chromatin in 
metaphase. Our findings also show that MUS81 S87 phosphorylation  
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is very low or undetectable in S-phase. The MUS81 complex (es) 
needs to be switched off during normal replication (Matos & West, 
2014), and downregulation of S87 phosphorylation is consistent with 
the need to avoid adventitious targeting of replication intermediates. 
Although MUS81 can form distinct heterodimeric complexes with 
EME1 or EME2 (Pepe & West, 2014b), our data show that 
phosphorylation of S87 is mainly detected in the MUS81-EME1 
complex. This is consistent with the MUS81-EME1 dimer being 
active in mitosis and suggests that different phosphorylation events 
may be involved in the regulation of specific MUS81 complexes. 
From this point of view, phosphorylation of the invariant subunit of 
the MUS81 heterodimers could be advantageous to direct association 
of MUS81 with EME1 or EME2, and to modulate endonucleolytic 
cleavage in vivo. From this point of view, although the amount of 
MUS81 in chromatin is unchanged by the S87 phosphorylation status, 
the different level of chromatin-associated EME1 or EME2 in the S87 
phosphorylation mutants of MUS81 may reflect the ability to form 
different complexes. Experiments using inhibitors of cell cycle 
kinases provided clues about consequences of unscheduled activation  
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of theMUS81 complex on viability and chromosome stability in 
human cells (Duda et al., 2016; Forment et al., 2011; Matos et al., 
2013a). Our findings clearly demonstrate that expression of a 
phosphomimic S87D-MUS81 mutant is detrimental to cell 
proliferation because of the generation of DSBs in S-phase cells. 
Interestingly, such unscheduled formation of DSBs in S-phase is 
largely prevented by ectopic expression of the bacterial RuvA protein. 
RuvA is a Holliday junction-binding protein, and its ectopic 
expression in human cells counteracts generation of DSBs by another 
structure-specific endonuclease, GEN1 (Malacaria, 2017b). Hence, 
from a mechanistic point of view, a mutation mimicking constitutive 
phosphorylation of MUS81 at S87 is sufficient to unleash targeting of 
HJ-like intermediates arising during normal replication and this is 
linked to generation of DNA damage. Much more interestingly, under 
unperturbed cell growth, expression of the S87D-MUS81 mutant 
results in a chromosome fragility phenotype, which is more marked 
than that observed in cells expressing the unphosphorylable S87A-
MUS81 form. In addition, cells expressing the phosphomimic S87D-
MUS81 mutant not only have elevated number of chromosome breaks  
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and gaps, but also have a striking accumulation of radial 
chromosomes. Since the presence of radial chromosomes is associated 
with repair of DSBs at collapsed forks by NHEJ (Kasparek & 
Humphrey, 2011), unscheduled  formation of DSBs by MUS81 
complex in S-phase may engage end-joining repair in addition to 
homologous recombination, which may promote gross chromosomal 
rearrangements. In unperturbed cells, loss of the MUS81 complex 
function results in mitotic defects including accumulation of bulky 
anaphase bridges (Garner et al., 2013; Matos et al., 2013a).We show 
that cells expressing the S87A-MUS81 mutant recapitulate the high 
number of bulky anaphase bridges observed in cells depleted of 
MUS81, although they show few chromosome-breaks in metaphase. 
In contrast, expression of the phosphomimic S87D-MUS81 results in 
few bulky anaphase bridges, but in a striking chromosome fragility. 
Hence, formation of DSBs by an unscheduled function of theMUS81 
complex during a normal S-phase is expected to be much more 
detrimental to genome stability of that associated with activation of 
the MUS81 complex at collapsed replication forks, while loss of 
resolution activity in early mitosis is better sustained, probably  
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because of backup activities  (Franchitto et al., 2008; Murfuni et al., 
2012; Murfuni et al., 2013a). Prolonged or pathological replication 
fork arrest has been associated to induction of MUS81-dependent 
DSBs(Hanada et al., 2007; Hengel et al., 2016; Murfuni et al., 2012; 
Murfuni et al., 2013a). Our data show that MUS81 S87 
phosphorylation is low in cells treated with HU for 24 h, a condition 
known to promoteMUS81 function at collapsed replication forks 
(Hanada et al., 2007), indicating distinct regulatory mechanisms of the 
human MUS81 complex during mild or persisting replication stress. 
However, we also provide evidence that CK2 inhibition reverts 
formation of MUS81-dependent DSBs after HU treatment. Hence, 
CK2-dependent phosphorylation on other residues ofMUS81 or 
EME1/2may be involved in regulating the MUS81 complex under 
different conditions, as reported in yeast (Dehé et al., 2013; Kai et al., 
2005). Alternatively, CK2 may target other proteins required for 
MUS81 complex function under conditions of persisting replication 
stress. Interestingly, CK2 phosphorylates, among others, the RAD51 
recombinase (Yata et al., 2012). Of note, RAD51 or RAD52 are 
involved in the formation of the MUS81 complex substrates at  
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demised replication forks (Hengel et al., 2016; Murfuni et al., 2013b). 
Clarifying this interesting point clearly goes beyond the scope of this 
work and deserves future investigations. In contrast to persisting or 
pathological replication stress, a mild condition of replication 
perturbation that does not arrest cells in S-phase can stimulate S87 
phosphorylation of MUS81. Such mild condition of replication stress 
has been reported to trigger the function of theMUS81-EME1 
complex to resolve intermediates at under-replicated regions, such as 
common fragile sites (Naim et al., 2013; Ying et al., 2013b). Our data 
on the cell cycle-specificity of MUS81 S87 phosphorylation suggest 
that this function of the MUS81 complex occurs post replication or in 
mitosis when common fragile sites loci might conclude their 
replication (Minocherhomji et al., 2015a). Strikingly, expression of 
the unphosphorylable MUS81 S87A mutant enhances chromosomal 
damage in cells treated with low-dose Aph only slightly, while the 
presence of a phosphomimic MUS81 mutant dramatically increases 
the amount of chromosome breakage and radial chromosomes after a 
mild replication stress. Hence, as in untreated cells, the phenotype 
deriving from unscheduled targeting of perturbed replication forks by  
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the MUS81 complex predominates over that resulting from loss of 
function in G2/M. Our experiments indicate that phosphorylation of 
MUS81 S87 is important to establish a correct interaction between 
MUS81 and SLX4. SLX4 is a versatile scaffold involved in 
recruitment of multiple endonucleases (Muñoz et al., 2009; Svendsen 
et al., 2010b). In particular, activation of MUS81/EME1 in mitotic 
cells requires association with SLX4 through a region localized in the 
first 90 aminoacids of MUS81 (Duda et al., 2016; Nair et al., 2014; 
Wyatt et al., 2013). Interestingly, deletion of the SLX4-interacting 
region of MUS81 broadens substrate specificity, allowing the complex 
to target much more easily also replication intermediates at perturbed 
forks(Wyatt et al., 2017). Serine 87 is within the region interacting 
with SLX4 and its phosphorylation makes MUS81 more prone to 
associate with SLX4, providing a mechanistic explanation to the 
unscheduled targeting by the MUS81 S87D protein of HJ-like and 
possibly other branched intermediates during replication. It has been 
recently reported that inhibition of WEE1 licences association of 
MUS81/EME2 with SLX4 resulting in a wide chromosome instability 
in the form of pulverized metaphases (Duda, et al., 2016).  
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Interestingly, the dramatic effect of WEE1 inhibition on premature 
cell cycle progression and chromosome pulverization is completely 
prevented by the unphosphorylable MUS81 S87A mutant, reinforcing 
the strong functional value of S87 phosphorylation. In our 
experimental conditions, however, depletion of EME2 substantially 
reduces but does not suppress WEE1i-associated phenotypes. In 
particular, expression of the S87D-MUS81 mutant induces a 
phenotype that is only minimally affected by EME2 depletion. As S87 
phosphorylation occurs mainly in theMUS81/EME1complex, it is 
conceivable that expression of the phosphomimic protein favours 
engagement of the MUS81/EME1 complex while, in wild-type cells, 
both complexes might contribute to the WEE1i-dependent 
phenotypes. Alternatively, the relative amount of each MUS81 
complex may be cell-specific and affect also the genetic dependency 
of the WEE1i-dependent effects. Moreover, as WEE1-mediated 
promotion of MUS81/SLX4 interaction involves CDK1-dependent 
phosphorylation of SLX4 (Duda, et al., 2016), our data indicate that 
both the partners must be modified to promote a productive 
interaction. CK2 is a crucial kinase in mitosis, and is positively  
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regulated byCDK1 (22). From this point of view, human cells might 
have evolved a redundant regulatory mechanism to restrainMUS81 
complex activity in late G2 and M phase. Indeed, elevated CDK1 level 
may directly contribute to activate the MUS81 complex 
phosphorylating EME1(Mankouri et al., 2013), while, indirectly, may 
enhance activity of CK2 that, in turn, targets MUS81 licensing 
interaction with an already phosphorylated SLX4 (Fig. 37). This 
elaborate regulatory mechanism will allow cleavage of branched DNA 
intermediates during a narrow window at the beginning of mitosis, 
contributing to limit chromosome instability. Our results may also 
have strong implications for the onset of genome instability in cancer. 
Indeed, CK2 has been found overexpressed in many human 
tumours(Ruzzene & Pinna, 2010). Hence, it is tempting to speculate 
that in CK2-overexpressing cancer cells also the biological function 
of MUS81/EME1 may be elevated and contribute strongly to genome 
instability and, possibly, aggressiveness. Further studies will be 
needed to evaluate the status ofMUS81 S87 in human tumours 
together with level and type of genome instability, in order to see if 
there is any correlation with the expression of CK2. Altogether, our  
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study provides the first mechanistic insight into the regulation of the  
human MUS81 complex, with functional implications on the 
consequences of deregulated processing of replication intermediates 
during unperturbed or minimally-perturbed DNA replication.  
 
 
Figure 37 Summarizing model to illustrate the contribution of CK2-dependent 
phosphorylation to the MUS81/EME1/SLX4 regulation. 
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A regulated mitotic function of MUS81 correlates with 
proliferation and chemosensitivity of BRCA2-deficient cells  
The role of BRCA2 in HR has been a subject of active investigation 
for many years. HR repairs DNA lesions including DNA double-
strand breaks (DSBs) using a homologous DNA sequence, typically 
the sister chromatid in mitotic cells. BRCA2 plays an essential role in 
this process by loading RAD51 recombinase onto single-stranded 
DNA formed at DSBs, where the RAD51 nucleoprotein filaments 
form and catalyze the subsequent strand invasion reaction (Feng & 
Jasin, 2017b). Fork protection is an additional BRCA2-mediated 
process that helps safeguard genomic integrity (Schlacher et al., 2011). 
Our findings reveal that S87-MUS81 phosphorylation is required for 
proliferation and to prevent DNA damage and segregation defects 
under unperturbed cell growth in BRCA2-deficient cells. In particular, 
it is worth noting that abrogation of S87-MUS81 phosphorylation 
recapitulates most of the phenotypes induced by MUS81 down-
regulation in unperturbed BRCA2-deficient cells (Lai et al., 2017). 
Since abrogation of S87 phosphorylation of MUS81 by CK2 impairs 
the function of the MUS81 complex in mitosis but is unrelated with 
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that performed in S-phase (Palma, Pugliese et al., 2018), our data 
suggest that is the mitotic function of MUS81 to be more relevant for 
proliferation in the absence of BRCA2. Consistent with this, depletion 
of BRCA2 increases two-fold S87 phosphorylation, which occurs 
exclusively outside S-phase. Very recently, MUS81 has been involved 
in flap cleavage at stalled forks that undergo degradation in the 
absence of BRCA2 (Lemaçon et al., 2017b). As this S-phase-related 
function of MUS81 would take place after replication fork stalling, 
while requirement of mitotic function of MUS81 would take place 
under unperturbed cell growth, it is likely that loss of BRCA2 evokes 
at least two independent mechanisms in which the MUS81 complex 
participates, possibly through independent regulatory networks. 
Alternatively, it might be possible that loss of mitotic MUS81 
regulation somehow requires BRCA2 function as a back-up and not 
vice versa. Two recent studies reported that MUS81 nuclease supports 
fork restart in the absence of BRCA2 by cleaving degraded forks to 
mediate fork restart (Lemaçon et al., 2017b; Rondinelli et al., 2017). 
Our data confirms that MUS81 provides a mechanism of replication 
stress tolerance in BRCA2-depleted cells but also show that  
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replication fork progression is affected in the absence of the mitotic 
phosphorylation of MUS81 at S87. Since S87 phosphorylation is 
undetectable in S-phase it may be possible that an impaired function 
of MUS81 in mitosis could lead to accumulation of DNA lesions or 
unprocessed intermediates in the subsequent S-phase, which requires 
BRCA2-dependent repair/processing. Indeed, loss of MUS81 or its 
S87 phosphorylation results in segregation defects and more 53BP1 
NBs in the subsequent G1-phase (Palma, Pugliese  et al., 2018; Naim 
et al. 2013; Ying et al. 2013c) and we also observe that depletion of 
BRCA2 leads to DNA damage accumulation in cells stably-depleted 
of MUS81 or in MUS81S87A cells.  Of note, the identity of the 
intermediate targeted by MUS81 complex at the demised fork is still 
uncertain (Malacaria et al., 2017a) and the increase of DNA damage 
that we have seen by γ-H2AX immunofluorescence seems not derive 
from processing of DSBs, as they are not affected by BRCA2 
depletion. One possibility is that loss of mitotic function of MUS81 
and BRCA2 could stimulate  accumulation of single-strand DNA 
lesions at or behind the forks (Kolinjivadi et al., 2017). Interestingly, 
we show that loss of MUS81 or its mitotic regulation equally  
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abrogates the delayed S-M progression observed upon BRCA2-
depletion. The enhanced DNA damage detected in S87MUS81-
expressing cells when BRCA2 is depleted and the defective S-M delay 
would suggest that the mitotic function of MUS81 is needed to delay 
and deal with defects associated with BRCA2-depletion while, in turn, 
loss of MUS81 mitotic function increases the need for BRCA2 
function in S-phase. Clarifying these interesting points deserves future 
investigation. Formation of anaphase bridges in BRCA2-deficient has 
been previously reported in mouse embryonic stem cells (Laulier et 
al.,, 2011). As expected, MUS81 inactivation in BRCA2-depleted 
cells led to a significantly higher percentage of cells with DAPI-
positive bridges relative to BRCA2 depletion alone (Fig.35B). 
Strikingly, expression of the unphosphorylable MUS81 S87A mutant 
enhances bulky bridges formation in cells treated with siBRCA2, 
while the absence of BRCA2 in phosphomimic MUS81 mutant 
increments DAPI-positive bridges formation relative to MUS81S87D 
alone. Differently from what we demonstrate in cells treated with low-
dose of Aph (Palma,  Pugliese et al., 2018), in this context, when we 
depleted BRCA2, the phenotype arise from the failure to  
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phosphorylate MUS81 during S-phase predominates over that 
resulting from constitutive S87 phosphorylation. We have 
demonstrated that cells have evolved an elaborate regulatory 
mechanism that allow MUS81 S87 phosphorylation during a narrow 
window at the beginning of mitosis, but in absence of BRCA2 this 
control it could be lost and it is conceivable that S87 phosphorylation 
could limit chromosome instability. This observation could be 
consistent with the reduction formation of 53BP1 NBs in G1 cells in 
MUS81S87D cells after BRCA2-depletion (Fig.35E).Loss of BRCA2 
sensitizes cells to PARP1 inhibitors(Ding et al., 2016; Lord & 
Ashworth, 2016; Ying, Hamdy, & Helleday, 2012). Interestingly, 
while we observe that loss of S87 phosphorylation seems to synergize 
with PARP1 inhibition in BRCA2-depleted cells, constitutive 
phosphorylation of MUS81 at S87 confers resistance to PARP1 
inhibitors. PARP1 inhibitors have been recently approved for 
treatment of BRCA-mutant breast and ovarian cancers, however, not 
all patients respond to this therapy and resistance to these novel drugs 
remains a major clinical problem (Pujade-Lauraine et al., 2017; 
Bouwman and Jonkers, 2014; Bitler et al., 2017; Lim and Tan, 2017).  
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Several mechanisms of chemoresistance in BRCA2-deficient cells 
have been identified and, rather than restoring normal recombination, 
these mechanisms result in stabilization of stalled replication forks 
(Clements et al., 2018). For instance, depletion of ZRANB3, HLTF or 
SMARCAL1 abolishes formation of the reversed fork structures 
targeted by the MRE11 nuclease and thus results in chemoresistance 
of BRCA2-deficient cells (Taglialatela et al., 2017). Inhibition of 
MRE11 (Schlacher et al., 2011; 2012), or of the RAD51 antagonist 
RADX (Dungrawala et al., 2017) can similarly rescue PARP1i 
sensitivity of BRCA2-deficient cells. Finally, inhibition of a parallel 
fork degradation pathway governed by the chromatin modifier EZH2 
which recruits the nuclease MUS81 to stalled forks (Rondinelli et al., 
2017), or channelling the processing stalled forks toward translesion 
synthesis-mediated lesion bypass rather than fork reversal 
(Guillemette et al., 2015), can also suppress chemosensitivity of 
BRCA2-deficient cells. Although unscheduled activation of MUS81 
through the phosphomimetic S87D mutation counteracts anaphase-
bridge in mitosis, it induces DSBs in S-phase (Palma, Pugliese et al., 
2018). Thus, it is conceivable that the S87D-MUS81 mutant rescues  
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PARPi sensitivity by cleaving stalled forks before fork reversal or 
immediately after bypassing the need for BRCA2-dependent fork 
protection. Formation of DSBs at replication forks, however, would 
call for enhanced HR and, thus, enhanced BRCA2 activation, making 
MUS81S87D cells sensitive to loss of BRCA2. However, this is not the 
case and MUS81S87D cells show wild-type sensitivity to concomitant 
depletion of BRCA2 (see Fig.36B). The higher resistance of 
MUS81S87D cells to concomitant siBRCA2 and treatment with 
Olaparib suggest that MUS81S87D may promote Olaparib resistance in 
BRCA2-deficient cells through activation of other DNA repair 
pathways. DSBs formed in S-phase can be repaired also by NHEJ and 
alt-NHEJ (Hartlerode & Scully, 2009; Polo & Jackson, 2011). The 
alternative end-joining may act on resected DNA ends, which likely 
form in S-phase because of elevated activity of CDK1/2 (Bonetti, 
Colombo, Clerici, & Longhese, 2018), and its function requires Ligase 
I/III (Chen et al. 2009; Simsek et al. 2011). Interestingly, we find that 
MUS81S87D cells depleted of BRCA2 are extremely sensitive to the 
Ligase I/III inhibitor L67 (Kasckow et al., 2013). In speculation, 
phosphomimic mutant forms of MUS81 activity could avail the  
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alt-NHEJ pathway to repair DSBs and preserve cell viability in cells 
lacking BRCA2. Another hypothesis is that, in BRCA2-depleted cells, 
the unscheduled regulation of MUS81 at S87 could result in 
processing of different types of DNA substrates not only during S-
phase leading to activation of backup repair pathway such as Alt-
NHEJ. The molecular mechanism behind our observation is not still 
clear and object of our future studies. Of note, recent studies have 
shown that BRCA1/2-deficient tumors upregulate Polθ-mediated 
alternative end-joining (alt-NHEJ) repair as a survival mechanism 
(Kais et al.,  2016), suggesting that deregulation of MUS81 function 
might be exploited in target therapy and as a biomarker for therapeutic 
selection. Combining the data presented in this second part of my 
thesis, we propose a model when the correlation between BRCA2 and 
MUS81 in preserve genome stability is strengthened by S87 
phosphorylation. Most importantly, according with our results, the 
resistance of BRCA2-depleted cells expressing MUS81S87D to PARPi 
but extreme sensitivity to Ligase I/III inhibition could be used as a 
potential biomarker for therapy of PARPi-resistant tumours having 
elevated levels of MUS81 activation. Since we demonstrate that CK2  
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phosphorylates MUS81 at Serine 87 (Palma,Pugliese et al., 2018) and 
CK2 is often over-expressed in tumours (Ruzzene & Pinna, 2010), 
also MUS81-S87 phosphorylation levels could be up-regulated. 
Hence, the understanding of the status of CK2 and consequent 
S87MUS81 in BRCAness human tumours may disclose better 
perspectives of prevention and novel therapeutic strategies. 
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